%PDF-1.3
%
4 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
11 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2019-05-07T04:32:57-07:00
2019-04-19T03:57:19+05:30
application/pdf
LRB-2018-0081-ver9-Moffatt_2P 127..134
uuid:1a2e77cb-4039-4251-baca-5df31afc74f6
uuid:bdafb346-1d29-40e0-8f89-260c84e05bbc
endstream
endobj
12 0 obj
<>stream
x+ |
endstream
endobj
13 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
14 0 obj
<>stream
x+ |
endstream
endobj
15 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
16 0 obj
<>stream
x+ |
endstream
endobj
17 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
18 0 obj
<>stream
x+ |
endstream
endobj
19 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
20 0 obj
<>stream
x+ |
endstream
endobj
21 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
22 0 obj
<>stream
x+ |
endstream
endobj
23 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
24 0 obj
<>stream
x+ |
endstream
endobj
25 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
26 0 obj
<>stream
x+ |
endstream
endobj
27 0 obj
<>stream
xS**T0T0 Bi yw*
endstream
endobj
29 0 obj
<>stream
/GS1 gs
BT
/F7 1 Tf
8.9663 0 0 8.9663 62.022 725.7825 Tm
0 0 0 rg
0 Tc
0 Tw
(LIMPRINT)Tj
/F4 1 Tf
9.843 0 0 9.843 72 709.3416 Tm
[(The)-236.1(acronym)-235.9(LIMPRINT)-238.4(stands)-232.1(for)-239.4(Lymphedema)-237(IMpact)]TJ
-1.0137 -1.1116 TD
[(and)-488.3(PRevalence-)-491.2(INTernational)-492.5(Lymphedema)-490.5(Framework)]TJ
0 -1.1174 TD
[(and)-206.1(presents)-206.7(the)-206.2(aim)-207.4(of)-203.8(the)-206.2(study,)-204.7(which)-203.5(is)-209.5()50.8(To)-206.1(determine)-204.9(the)]TJ
0 -1.1116 TD
[(impact)-350.2(and)-344.3(prevalence)-351(of)-342(chronic)-350(edema)-350(within)-341.9(health)-349(ser-)]TJ
T*
[(vices)-359.1(at)-354.8(a)-359.4(national)-357.1(and)-355.8(international)-358.3(level)-359.4(using)-356.8(a)-353.6(common)]TJ
0 -1.1174 TD
[(methodology.)49.8()]TJ
/F7 1 Tf
8.9663 0 0 8.9663 62.022 629.2345 Tm
[(LIMPRINT)-338.4(project)-331.5(overview)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 612.7936 Tm
(LIMPRINT)Tj
/F5 1 Tf
4.7172 0 TD
()Tj
/F4 1 Tf
1.3247 0 TD
[(was)-535(a)-532.1(two-phased)-538.3(project.)-532.1(Phase)-537.4(1)-531(was)]TJ
-7.0556 -1.1174 TD
[(conducted)-382.2(between)-386.6(June)-379.8(2013)-378.8(and)-378.8(June)-385.5(2014)-378.8(with)-379.9(the)-379(de-)]TJ
0 -1.1116 TD
[(velopment)-382.4(and)-384.6(validation)-382.5(of)-382.3(the)-384.7(methods)-384.4(within)-382.2(two)-378.7(large)]TJ
T*
[(pilot)-507(projects.)-504.2(Phase)-508.6(II)-509(involved)-505.6(roll)-505.7(out)-504.5(across)-503.8(all)-505.8(sites)]TJ
0 -1.1174 TD
[(\(9)-244.1(countries)-254.2(and)-246.4(40)-244.1(sites\))-249.5(from)-247.5(June)-247.3(2014)-240.6(until)-247.8(August)-249.3(2017.)]TJ
0 -1.1116 TD
[(Table)-285.6(1)-277.6(indicates)-284.3(the)-281.1(stages)-285.1(of)-278.6(the)-281.1(project)-286.7(plan.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 532.6298 Tm
[(Detailed)-334.4(Project)-334.9(Development)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 516.1888 Tm
[(The)-316.7(stages)-325.5(of)-319(the)-315.6(LIMPRINT)-324.8(study)-322.2(are)-316.6(described)-324.3(below.)]TJ
-1.0137 -1.1116 TD
[(While)-504.5(presented)-508.6(as)-504.3(sequential)-510(stages,)-507.4(many)-502.1(of)-509(them)-502.3(ran)]TJ
T*
[(concurrently)-287.6(over)-282(the)-281.1(development)-282.1(phase.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 62.022 468.9637 Tm
[(Phase)-333.1(1.)-336.7(Stage)-330.8(1.)-336.7(Agreement)]TJ
0 -1.2266 TD
[(of)-336.7(the)-328.5(research)-337.1(methodologies)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 441.5243 Tm
[(The)-236.1(approach)-242.7(taken)-238.3(for)-239.4(the)-240.7(LIMPRINT)-244.2(study)-235.8(was)-241.3(decided)]TJ
-1.0137 -1.1116 TD
[(du)20.8(ri)15(ng)-537.9(an)-539(in)20.7(te)19.6(rn)15.1(at)19.5(io)20.7(na)19.7(l)-548.4(I)0(L)19.7(F)-553.9(co)19.7(nf)20.9(er)19.7(en)19.7(ce)-540.2(in)-543.7(Mo)19.9(nt)20.7(pe)19.7(ll)20.6(ie)19.6(r)-554(i)0(n)]TJ
T*
[(20)20.8(12)20.8(.)]TJ
7.3823 0 0 6.5614 83.6787 424.0062 Tm
(2)Tj
9.843 0 0 9.843 89.2346 419.6408 Tm
[(Ke)18.8(y)-191.2(s)0(t)20.9(a)0(k)19.7(e)0(h)19.7(o)0(l)15(d)0(e)19.7(r)0(s)-180.5(f)0(r)20.9(o)0(m)-176.2(f)0(r)15.1(a)0(m)18.5(e)0(w)18.8(o)0(r)20.9(k)0(s)-180.6(a)0(n)19.7(d)-191.2(me)18.4(th)20.7(od)20.8(ol)20.7(og)20.8(is)15.2(ts)]TJ
-2.7647 -1.1174 TD
[(di)20.7(sc)14.1(us)21(se)19.9(d)-283.3(t)0(h)20.7(e)-278.7(st)15.1(re)19.7(ng)20.8(th)20.7(s)-283.1(a)0(n)19.7(d)-283.3(li)20.6(mi)19.5(ta)19.6(ti)20.6(on)20.8(s)-283.1(o)0(f)-272.9(d)0(i)20.7(f)0(f)20.9(e)0(r)19.7(e)0(n)13.9(t)-277.7(ep)19.7(id)15(em)18.5(io)20.7(-)]TJ
25.504 32.1564 TD
-.0194 Tc
[(l)-19.4(o)-4.4(g)-19.4(i)1.3(c)-19.4(a)-.9(l)-492.9(a)-19.4(p)-5.5(p)-19.4(ro)-19.4(ac)-19.4(he)-19.4(s)-489.1(w)-19.4(it)-19.4(hi)-19.4(n)-488.3(c)-19.4(om)-19.4(pl)-19.4(ex)-498.5(a)-19.4(n).3(d)-492.8(v)-19.4(ar)-19.4(ie)-19.4(d)-483.5(h)-19.4(ea)-19.4(lt)-19.4(h)-488.3(c)-19.4(ar)-19.4(e)]TJ
0 -1.1174 TD
0 Tc
[(sy)15.3(st)20.9(em)18.4(s.)-390.2(W)13.9(h)0(i)14.9(l)0(e)-389.4(i)0(t)-382.6(w)0(a)13(s)-392.6(ac)12.8(kn)20.8(ow)20(le)19.5(dg)20.8(ed)-389.3(th)20.7(at)-389.4(la)19.6(rg)20.9(e)-399.7(p)0(o)20.8(p)0(u)15.1(l)0(a)19.6(t)0(i)20.6(o)0(n)20.8(-)]TJ
0 -1.1116 TD
[(ba)13.9(se)19.9(d)-312.1(s)0(t)20.9(u)0(d)20.8(i)0(e)19.5(s)-311.9(we)18.8(re)-302.8(th)15(e)-313.3(g)0(o)20.8(l)0(d)-301.8(s)0(t)20.9(a)0(n)19.7(d)0(a)19.7(r)0(d)15.1(,)-308.7(th)20.7(is)-301.6(wa)18.8(s)-311.9(n)0(o)15.1(t)-306.5(a)-313.3(r)0(e)14(a)0(l)19.5(i)0(s)20.9(t)0(i)20.6(c)]TJ
T*
[(op)15.1(ti)20.6(on)-261.4(fo)20.9(r)-271.8(t)0(h)20.7(e)-273(fo)20.9(ll)20.6(ow)20(in)20.7(g)-271.8(r)0(e)19.7(a)0(s)19.9(o)0(n)15.1(s)0(:)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 323.0361 677.14 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 331.9369 675.8361 Tm
[(Lack)-336.2(of)-336.2(international)-335.2(resources)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 322.7527 664.8943 Tm
(B)Tj
/F4 1 Tf
9.843 0 0 9.843 331.9936 664.8943 Tm
[(Census)-336.7(or)-324.7(reliable)-335.2(general)-333.8(population)-329.4(data)-335.2(from)-328.1(which)]TJ
0 -1.1174 TD
[(to)-336.4(draw)-334.7(random)-337.3(samples.)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 322.7527 642.9542 Tm
(B)Tj
/F4 1 Tf
9.843 0 0 9.843 331.9936 642.9542 Tm
[(Insurance)-456.6(data)-450.4(for)-446.7(random)-452.5(sampling)-449(in)-445.8(public)-451.5(health)]TJ
0 -1.1116 TD
[(care)-341.9(systems)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 323.0361 622.3179 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 331.9369 621.014 Tm
[(Large)-331.5(populations)-336(would)-329.1(require)-332.6(screening)-335.8(to)-330.6(generate)]TJ
T*
[(a)-336.3(modest)-331.5(sampl)-7.8(e)-330.6(size)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 323.0361 600.4345 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 331.9369 599.1306 Tm
[(International)-294.7(coding)-290.1(systems)-297.6(do)-290.2(not)-285.7(exist)-294.7(to)-290.3(interrogate)]TJ
0 -1.1174 TD
[(existing)-338.5(data)-335.2(sets)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 323.0361 578.4943 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 331.9369 577.1904 Tm
[(Bias)-334.8(in)-336.4(population)-335.1(and)-332.8(health)-337.5(service)-339.4(data)-335.2(sets)]TJ
-.9043 -1.7222 TD
[(The)-299.4(core)-300.4(working)-296.7(group)-299.2(dened)-296.8(the)-298.3(key)-298.2(priority)-297.1(as)-302.7()50.8(The)]TJ
-1.0137 -1.1116 TD
[(need)-467.5(to)-463.1(uncover)-470.8(the)-465.4(hidden)-462.9(burden)-468.5(of)-462.9(chronic)-465.2(edema)-465.2(on)]TJ
T*
[(health)-239.6(services.)46.8()-231.4(A)-238.1(method)-233.8(of)-232.6(case)-238.1(ascertainment)-240.4(previously)]TJ
T*
[(used)-224.2(in)-215.4(the)-223.5(United)-222(Kingdom)-217.3(was)-218.3(adopted)-223.3(as)-222(the)-217.7(most)-218.7(exible)]TJ
0 -1.1174 TD
[(approach)-530.7(using)-523.8(the)-528.7(following)-529.5(public)-526.4(health)-527.6(denition)-523.9(of)]TJ
0 -1.1116 TD
[(chronic)-286.6(edema.)]TJ
7.3823 0 0 6.5614 373.7763 509.8392 Tm
(3,4)Tj
9.843 0 0 9.843 383.0172 505.4739 Tm
(:)Tj
/F11 1 Tf
-5.8922 -2.229 TD
[()50.8(Chronic)-500.5(edema)-498.3(is)-491.7(a)-496.4(broad)-494.9(term)-495.9(used)-494.9(to)-491.9(describe)]TJ
0 -1.1116 TD
[(edema,)-421.1(which)-411(has)-417.8(been)-415.7(present)-413(for)-417.9(more)-415.2(than)-413.5(three)]TJ
T*
[(months)-312.7(and)-308.6(involves)-311.9(one)-309.7(or)-307.3(more)-311.5(of)-313.4(the)-304.1(following)-311(ar-)]TJ
0 -1.1174 TD
[(eas:)-333.6(limbs,)-326.7(hands/feet,)-333.8(upper)-329(body)-328.1(\(breast/chest)-328.6(wall,)]TJ
0 -1.1116 TD
[(shoulder,)-646.7(back\),)-650.6(lower)-647(body)-644.9(\(buttocks,)-649.3(abdomen\),)]TJ
T*
[(genital)-285.7(\(scrotum,)-284.7(penis,)-280.7(vulva\),)-283.2(head,)-279.7(neck,)-282(or)-284.2(face.)52()]TJ
7.3823 0 0 6.5614 535.6912 433.1338 Tm
(3)Tj
/F7 1 Tf
8.9663 0 0 8.9663 313.0582 408.8125 Tm
[(Primary)-339.8(aim)-331.8(and)-335.7(secondary)-332.6(objectives)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 392.3716 Tm
[(The)-368.5(primary)-373(aim)-368.7(of)-370.8(LIMPRINT)-370.9(was)-368()50.8(To)-367.3(determine)-377.7(the)]TJ
-1.0137 -1.1116 TD
[(number)-561.9(of)-560.9(people)-556.2(within)-560.8(health)-562.1(services)-559.2(suffering)-563.9(from)]TJ
T*
[(chronic)-384.5(edema)-384.6(and)-378.8(its)-377.7(impact)-384.8(upon)-378.8(them.)46.2()-375.4(Many)-380.9(of)-382.3(these)]TJ
0 -1.1174 TD
[(people)-354.6(would)-346.3(not)-349(have)-346.6(been)-346.6(previously)-352(identied)-352.3(or)-347.8(be)-343.2(re-)]TJ
0 -1.1116 TD
[(ceiving)-286.8(treatment)-285.7(before)-279.6(screening)-284(during)-283.2(the)-281.1(study.)]TJ
ET
62.022 377.972 239.131 .22678 re
f
62.022 56.58 239.131 .22678 re
f
62.022 359.263 239.131 .28345 re
f
62.022 338.116 239.131 .22675 re
f
62.022 147.572 239.131 .28346 re
f
62.022 126.425 239.131 .22675 re
f
62.022 105.222 239.131 .28348 re
f
BT
/F8 1 Tf
9.845 0 0 9.845 131.1874 383.6408 Tm
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(1.)Tj
/F8 1 Tf
1.2496 0 TD
[(Project)-334.8(Plan)]TJ
/F11 1 Tf
-11.2752 -1.8427 TD
[(Phase)-335.4(1:)-336(Development)-334.3(and)-337(validation)]TJ
0 -2.1479 TD
(Stages)Tj
/F4 1 Tf
1.002 -1.9003 TD
[(1.)-257.7(Agreement)-262.2(of)-261.1(the)-263.5(research)-265.8(methodologies)-258.6(that)-264.6(could)-259.7(be)]TJ
.9847 -1.0077 TD
[(developed)-317.8(for)-319.7(international)-316.7(use)-320.7(in)-318.9(complex)-315.8(health)-319.6(care)]TJ
0 -1.0135 TD
(systems)Tj
-.9847 -1.0135 TD
[(2.)-332.6(Literature)-337.6(review)-337.5(of)-330.2(prevalence)-338.4(study)-333.2(methods)-337.5(and)]TJ
.9847 -1.0135 TD
(epidemiology)Tj
-.9847 -1.0077 TD
[(3.)-240.5(Development)-241.3(of)-243.8(questionnaires)-242.1(for)-239.1(the)-246.2(core)-242.4(and)-240.2(module)]TJ
.9847 -1.0135 TD
[(specialist)-336.3(tools)]TJ
-.9847 -1.0135 TD
[(4.)-332.6(Development)-339.2(and)-332.4(validation)-335.4(of)-330.2(a)-336.2(classication)-340.2(for)]TJ
.9847 -1.0135 TD
[(chronic)-331.9(edema)]TJ
-.9847 -1.0077 TD
[(5.)-332.6(Interrater)-336.2(reliability)-336.8(studies)-336.3(\(pitting)-336.9(test)-333.5(and)]TJ
.9847 -1.0135 TD
[(classication)-334.5(of)-336(chronic)-331.9(edema)-337.9(in)-336.2(different)]TJ
T*
(populations\))Tj
-.9847 -1.0077 TD
[(6.)-332.6(Construction)-336.9(and)-332.4(testing)-336.7(of)-330.2(the)-338.3(online)-329.9(database)]TJ
0 -1.0135 TD
[(7.)-257.7(Development)-258.6(of)-255.4(an)-262.3(international)-259.1(protocol)-257.1(and)-257.5(sampling)]TJ
.9847 -1.0135 TD
(frameworks)Tj
-.9847 -1.0135 TD
[(8.)-332.6(Development)-339.2(of)-330.2(a)-336.2(support)-335.2(manual)-332.1(and)-332.4(educational)]TJ
.9847 -1.0077 TD
(tools)Tj
-.9847 -1.0135 TD
[(9.)-332.6(Establishment)-334.6(of)-336(quality)-336.9(control)-330.9(mechanisms)]TJ
/F11 1 Tf
-1.002 -2.4013 TD
[(Phase)-335.4(2:)-336(Main)-333.4(study)]TJ
0 -1.9003 TD
(Stages)Tj
/F4 1 Tf
1.002 -2.1479 TD
[(1.)-332.6(Epidemiology)-332.6(studies)-336.3(undertaken)-336.1(in)-336.2(all)-332.7(participating)]TJ
.9847 -1.0135 TD
(sites)Tj
-.9847 -1.0135 TD
[(2.)-332.6(Data)-335.5(quality)-336.9(monitoring)]TJ
T*
[(3.)-332.6(Data)-335.5(analysis)-338.5(and)-332.4(reporting)]TJ
ET
313.058 295.767 239.131 .28348 re
f
313.058 56.58 239.131 .22678 re
f
313.058 277.115 239.131 .22675 re
f
313.058 236.013 239.131 .22676 re
f
313.058 214.866 239.131 .22676 re
f
BT
/F8 1 Tf
9.845 0 0 9.845 346.507 311.4141 Tm
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(2.)Tj
/F8 1 Tf
1.2496 0 TD
[(Primary)-335.8(and)-332(Secondary)-331.7(Aims)]TJ
1.4742 -1.0077 TD
[(of)-331.2(LIMPRINT)]TJ
/F11 1 Tf
-9.1215 -1.8427 TD
[(Primary)-338.2(aim)]TJ
/F4 1 Tf
0 -1.9003 TD
[(To)-337.1(determine)-336.4(the)-332.6(prevalence)-338.4(and)-338.1(functional)-335.2(impact)-332.3(of)]TJ
.9962 -1.0135 TD
[(chronic)-331.9(edema)-337.9(within)-335.5(health)-336.9(services)-333.8(at)-337.3(a)-330.4(national)-339(and)]TJ
0 -1.0077 TD
[(international)-334(level)-335.9(using)-333.2(modular)-337.7(epidemiological)-338.3(tools.)]TJ
/F11 1 Tf
-.9962 -2.4071 TD
[(Secondary)-340.5(objectives)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 322.9228 203.6976 Tm
()Tj
/F4 1 Tf
9.845 0 0 9.845 331.8235 202.3937 Tm
[(To)-331.4(identify,)-335.5(using)-338.9(a)-330.4(case)-335.5(ascertainment)-342.7(questionnaire)]TJ
.0806 -1.0135 TD
[(\(CORE)-337.2(TOOL\),)-334.8(all)-332.7(patients)-338.9(within)-335.5(dened)-330.6(health)]TJ
T*
[(services)-339.5(within)-329.8(participating)-339.7(countries,)-337.3(who)-332(currently)]TJ
0 -1.0077 TD
[(suffer)-335.2(from)-333.4(chronic)-337.7(edema)-332.1(of)-336(longer)-335.5(than)-333.5(3)-335(months)]TJ
0 -1.0135 TD
(duration.)Tj
/F9 1 Tf
7.9702 0 0 7.9702 322.9228 153.8645 Tm
()Tj
/F4 1 Tf
9.845 0 0 9.845 331.8235 152.5606 Tm
[(To)-296.8(determine)-301.9(the)-303.8(impact)-297.7(of)-301.4(chronic)-297.4(edema)-303.3(on)-301.4(the)-298(lives)]TJ
.0806 -1.0135 TD
[(of)-330.2(patients)-338.9(using)-333.2(questionnaires)-340(as)-331.2(follows:)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 332.5038 132.6613 Tm
(B)Tj
/F4 1 Tf
9.845 0 0 9.845 341.7448 132.6613 Tm
[(Demographic)-339(and)-332.4(disability)-334.3(assessment)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 332.5038 122.6834 Tm
(B)Tj
/F4 1 Tf
9.845 0 0 9.845 341.7448 122.6834 Tm
[(Health-related)-338(quality)-336.9(of)-336(life)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 332.5038 112.7055 Tm
(B)Tj
/F4 1 Tf
9.845 0 0 9.845 341.7448 112.7055 Tm
[(Details)-338.7(of)-330.2(swelling)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 332.5038 102.7842 Tm
(B)Tj
/F4 1 Tf
9.845 0 0 9.845 341.7448 102.7842 Tm
[(Wound)-335.3(assessment)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 332.5038 92.8063 Tm
(B)Tj
/F4 1 Tf
9.845 0 0 9.845 341.7448 92.8063 Tm
[(Cancer)-338.7(assessment)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 322.9228 84.1323 Tm
()Tj
/F4 1 Tf
9.845 0 0 9.845 331.8235 82.8283 Tm
[(To)-331.4(estimate)-341.2(the)-332.6(proportion)-332.7(of)-336(patients)-333.1(with)-339.1(chronic)]TJ
.0806 -1.0135 TD
[(edema)-314.8(who)-309(also)-310.3(have)-311.5(a)-313.1(wound)-311(in)-313.1(the)-309.5(same)-312.5(anatomical)]TJ
0 -1.0077 TD
(area)Tj
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(128)Tj
46.3153 0 TD
[(MOFFATT)-333.6(ET)-338.7(AL.)]TJ
ET
endstream
endobj
43 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 69.7323 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(Secondary)-347.3(objectives)-343(were)-341.6(dened)-342.8(to)-342.1(fulll)-340.9(the)-344.4(scope)-341.7(of)]TJ
-1.0137 -1.1174 TD
[(the)-200.4(project)-206.1(and)-200.3(were)-203.4(used)-201.2(to)-198.2(determine)-204.9(the)-200.4(study)-201.3(methods)-200.1(and)]TJ
0 -1.1116 TD
[(the)-281.1(modular)-286.7(data)-283.3(collection)-280(tools)-282(\(Table)-286.7(2\).)]TJ
1.0137 -1.1116 TD
[(The)-512.5(project)-511.4(aimed)-516(to)-509.2(facilitate)-517.4(the)-505.7(following)-512.2(types)-513.5(of)]TJ
-1.0137 -1.1116 TD
[(studies)-285.2(within)-284.3(each)-278.6(country:)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 69.7323 666.1416 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 78.633 664.8943 Tm
[(Facility-based)-377.3(prevalence)-374(studies:)-372.8(for)-371.9(example,)-373.1(a)-370.9(gen-)]TJ
0 -1.1174 TD
[(eral)-335.1(hospital)-338.5(or)-330.5(nursing)-335.9(home)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 69.7323 644.2581 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 78.633 642.9542 Tm
[(Geographically)-320.8(based)-318.7(prevalence:)-317.7(patients)-316.6(identied)-317.7(in)]TJ
0 -1.1116 TD
[(all)-333(health)-337.5(services)-340.3(within)-336.2(a)-330.6(dened)-337.1(area)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 69.7323 622.3179 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 78.633 621.014 Tm
[(Specic)-581.2(patient)-580.6(populations:)-579.2(for)-579.2(example,)-580.4(specialist)]TJ
T*
[(lymphedema)-339.6(services,)-338(wound)-334.7(care)-336.2(clinics)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 69.7323 600.4345 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 78.633 599.1306 Tm
[(In-depth)-522.7(evaluation)-527.5(of)-520.5(a)-520.6(random)-521.6(sample)-522.7(of)-520.5(patients)]TJ
0 -1.1174 TD
[(\(within)-389.1(facility-)-387.1(and)-384.6(geographically)-394.8(based)-387.8(studies\))-384.2(for)]TJ
0 -1.1116 TD
[(example,)-338.5(to)-330.6(classify)-339.3(type)-334(of)-336.2(chronic)-332.7(edema)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 552.2455 Tm
[(Study)-338.6(infrastructure)-332.2(support)-332.7(and)-335.7(patient)-331.5(involvement)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 535.8046 Tm
[(An)-446.6(international)-456.2(steering)-448.9(group)-449(of)-445.7(relevant)-450.3(experts,)-451.1(in-)]TJ
-1.0137 -1.1116 TD
[(cluding)-222.2(lymphologists,)-226.5(epidemiologists,)-225.4(and)-217.6(statistician)-11.3(s)-219.8(met)]TJ
0 -1.1174 TD
[(quarterly)-363.8(throughout)-362.6(the)-361.7(project)-361.6(to)-359.4(ensure)-365.8(project)-361.6(delivery.)]TJ
0 -1.1116 TD
[(A)-336(separate)-330.1(data)-335.2(monitoring)-335.1(committee)-333(was)-333.4(available)-331.7(to)-330.6(an-)]TJ
T*
[(swer)-282.7(any)-280.9(questions)-287.4(relating)-282.2(to)-278.8(data)-283.3(issues.)]TJ
1.0137 -1.1174 TD
[(Individual)-444.5(patients)-443.3(and)-442.2(patient)-442.4(organizations)-444.2(within)-439.8(the)]TJ
-1.0137 -1.1116 TD
[(national)-190.1(frameworks)-187.9(were)-180.4(involved)-188.8(in)-180.9(all)-183.3(aspects)-189.5(of)-180.7(the)-183.1(study,)]TJ
T*
[(which)-364.8(conformed)-364.8(to)-359.4(current)-361.4(guidance)-363.8(for)-366.1(patient)-361.8(and)-361.6(carer)]TJ
T*
[(participation)-289.1(\(INVOLVE)-285.3(guidelines\).)]TJ
7.3823 0 0 6.5614 208.6299 452.5227 Tm
(5)Tj
9.843 0 0 9.843 69.7323 437.1589 Tm
[(All)-292.4(countries)-294.5(and)-292.4(sites)-294.5(used)-293.4(the)-292.6(international)-294.9(study)-293.4(proto-)]TJ
-1.0137 -1.1116 TD
[(col)-499.9(and)-499.8(conducted)-503.1(the)-499.9(research)-502.8(in)-497.7(accordance)-507.5(with)-500.9(their)]TJ
T*
[(current)-430.6(ethical)-426.3(and)-424.9(research)-427.9(governance)-424.6(regulatory)-428.2(frame-)]TJ
0 -1.1174 TD
[(works)-461.2(and)-465.2(the)-459.6(International)-461.8(Declaration)-467.3(of)-457.2(Helsinki.)]TJ
7.3823 0 0 6.5614 278.0219 408.6424 Tm
(6)Tj
9.843 0 0 9.843 286.2425 404.2771 Tm
(All)Tj
-23.01 -1.1116 TD
[(sites)-380.9(complied)-375.5(with)-374.2(standard)-379.7(operating)-381.1(procedures)-377.1(on)-376.6(con-)]TJ
T*
[(ducting)-285.6(the)-281.1(study)-281.9(and)-280.9(quality)-280(control)-285.6(mechanisms.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 357.392 Tm
[(Patient)-337.7(inclusion)-336.4(and)-329.4(exclusion)-339(criteria)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 340.9511 Tm
[(The)-310.9(study)-310.7(patient)-309.9(inclus)-7.8(ion)-308.7(and)-309.7(exclusion)-311.8(criteria)-312.1(are)-310.9(de-)]TJ
-1.0137 -1.1116 TD
[(ned)-281.9(in)-284.6(Table)-279.9(3.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 305.0645 Tm
(Methods)Tj
/F4 1 Tf
9.843 0 0 9.843 69.7323 288.6236 Tm
[(To)-291.4(comply)-297.1(with)-293.5(the)-292.6(overall)-298.3(study,)-291.1(the)-292.6(presence)-301.2(and)-292.5(chro-)]TJ
-1.0137 -1.1116 TD
[(nicity)-561.1(of)-560.9(edema)-563.2(was)-558.1(conrmed)-559.4(by)-560.9(two)-557.2(methods)-563(before)]TJ
0 -1.1174 TD
[(chronic)-280.8(edema)-275.2(was)-281.6(judged)-272.8(to)-278.8(be)-274.1(present.)-278.3(This)-276.2(screening)-284(test)]TJ
25.5097 46.5787 TD
[(was)-321.9(undertaken)-319.9(at)-320.3(each)-324.7(participating)-323.7(site)-322.4(by)-319(staff)-317.6(trained)-327(in)]TJ
0 -1.1174 TD
[(the)-355.9(data)-364(collection)-360.6(methods.)-359.1(In)-359.3(specialist)-366(lymphedema)-362.7(ser-)]TJ
0 -1.1116 TD
[(vices,)-235.8(all)-235.1(patients)-236(had)-234.9(been)-237.1(assessed)-241.9(by)-232.6(lymphologists)-234.6(before)]TJ
T*
[(data)-381.2(collection)-383.6(and)-378.8(the)-379(classication)-381.8(of)-382.3(the)-379(chronic)-378.7(edema)]TJ
T*
[(dened.)-334.8(Further)-331.3(description)-337.2(of)-330.5(the)-332.9(methods)-332.6(required)-339.5(in)-330.6(dif-)]TJ
0 -1.1174 TD
[(ferent)-279.7(health)-285.7(care)-284.3(settings)-280.7(is)-278.6(dened)-285.2(below.)]TJ
/F11 1 Tf
1.0137 -1.1116 TD
[(Conrmation)-192.7(of)-192.4(chronic)-188.5(edema)]TJ
/F4 1 Tf
12.5562 0 TD
[(was)-189.5(based)-191.9(on)-192.3(the)-194.7(following)]TJ
-13.5699 -1.1116 TD
[(two)-280.8(factors:)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 320.8251 633.3164 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 329.6692 632.0125 Tm
[(First,)-319.8(the)-309.9(existence)-319.9(of)-313.2(edema)-321.3(was)-316.2(determined)-315.5(based)-318.7(on)]TJ
0 -1.1174 TD
[(an)-706(observational)-709.1()50.8(Pitting)-706.1(Edema)-707.2(Test,)46.4()-703.7(which)-710.4(is)]TJ
0 -1.1116 TD
[(widely)-360.2(used)-356.7(in)-353.7(clinical)-358.4(practice)-365(and)-355.8(been)-358.1(shown)-351.8(to)-359.4(be)]TJ
T*
[(valid)-346.7(and)-338.5(reliable.)]TJ
7.3823 0 0 6.5614 402.633 603.4959 Tm
(7)Tj
9.843 0 0 9.843 409.6629 599.1306 Tm
[(The)-345.5(pitting)-336.5(test)-345.5(was)-339.2(carried)-345.3(out)-343.3(by)]TJ
-8.1269 -1.1174 TD
[(pressing)-349.5(the)-344.4(thumb)-346.7(into)-344.5(the)-344.4(site)-345.5(of)-342(the)-344.4(swelling)-345.1(for)-348.8(10)]TJ
0 -1.1116 TD
[(seconds.)-422(If)-416.8(a)-417(pit)-418.3(remained)-422.6(upon)-413.3(removal)-420.3(of)-416.9(pressure,)]TJ
T*
[(then)-587.4(pitting)-584.2(edema)-592(was)-586.9(judged)-583.9(to)-584.1(be)-585.1(present.)-589.3(The)]TJ
T*
[(presence)-295.5(of)-295.9(edema)-292.5(was)-293.1(tested)-291.2(in)-290.3(all)-292.7(body)-292.4(parts,)-292.2(using)-293.4(a)]TJ
0 -1.1174 TD
[(standard)-276(protocol,)-267.1(including)-270.7(the)-269.5(upper)-265.8(and)-269.4(lower)-272.6(limbs,)]TJ
0 -1.1116 TD
[(trunk,)-337.3(face,)-333.8(and)-338.5(neck.)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 320.8251 523.6723 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 329.6692 522.425 Tm
-.0156 Tc
[(S)-15.6(e)10(cond)-15.6(,)-354.2(e)-.6(dema)-369.2(was)-362.1(j)-15.6(u)10.9(dged)-368(t).5(o)-362.3(b)-15.6(e)-353(c)-.6(hr)-15.6(o)11(n).6(ic)-369.2(if)-362.2(i)-15.6(t)-352.1(had)-368(b).6(een)]TJ
0 -1.1174 TD
[(p)-15.7(r)10.9(esen)-15.7(t)-236.9(for)-247.2(3)-247.2(m)-.7(ont)-15.7(h)10.8(s)-247(or)-247.1(more)-15.7(.)-234.5(T)-.7(hi)-15.7(s)-236.7(f).5(acto)-15.7(r)-236.7(was)-247(d).5(et)-15.7(e)9.6(r).5(mined)]TJ
0 -1.1116 TD
-.0159 Tc
[(o)-15.9(n)-323.4(th)-15.9(e)-324.5(b).3(as)-15.9(i)10.8(s)-339.3(of)-333.7(f)-15.9(e)9.6(edbac)-15.9(k)-324.5(re)-15.9(c)8.4(e)-.9(ived)-339.5(fro)-15.9(m)-324.6(t).1(he)-340.7(pati)-15.9(e)9.4(n).3(t,)-336.1(o)-15.9(r)-323.3(if)]TJ
T*
[(t)-15.9(h)10.6(is)-483.3(was)-489.1(not)-483.7(pos)-15.9(s)11.1(i).1(bl)-15.9(e)9.4(,)-480.1(f)-15.9(r)10.8(om)-484.8(care)-15.9(r)9.6(s)-483.3(a)-.9(nd)-483.5(cl)-15.9(i)10.4(n).3(ici)-15.9(a)9.4(ns)-483.3(who)]TJ
0 -1.1174 TD
-.0158 Tc
[(h)-15.8(a)9.6(ve)-334.8(kno)-15.8(w)9.9(n)-333.7(the)-334.8(p).4(er)-15.8(s)11(o).4(n)-333.7(f)-15.8(o)10.8(r)-333.7(at)-333.8(lea)-15.8(s)9.8(t)-333.8(3)-333.7(mont)-15.8(h)10.7(s).6(.)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 320.8251 468.907 Tm
0 Tc
()Tj
/F4 1 Tf
9.843 0 0 9.843 329.6692 467.603 Tm
[(In)-606.9(community)-601.3(nursing)-606.6(home)-605.8(studies)-602(in)-601.3(the)-603.6(United)]TJ
0 -1.1116 TD
[(Kingdom,)-295.6(additional)-290.3(questions)-293.2(were)-295.6(included)-287.9(to)-290.3(ensure)]TJ
T*
[(that)-339.9(the)-332.9(clarication)-340.7(of)-330.5(chronic)-338.4(edema)-332.8(was)-339.2(correct.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 310.8472 423.7227 Tm
[(Phase)-333.1(1.)-330.4(Stage)-337.2(2.)-330.4(Literature)-340.2(review)-332.7(of)-330.4(prevalence)]TJ
0 -1.2203 TD
[(study)-333.9(methods)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 396.3401 Tm
[(A)-336(literature)-343.3(review)-338.2(of)-342(the)-338.7(current)-338.4(evidence)-341.9(had)-338.5(been)-340.8(un-)]TJ
-1.0137 -1.1116 TD
[(dertaken)-237(under)-237(the)-240.7(leadership)-239.2(of)-238.3(the)-235(American)-244.9(Lymphedema)]TJ
T*
[(Framework)-503.7(Project)-505.4(\(ALFP\).)]TJ
7.3823 0 0 6.5614 427.181 378.8219 Tm
(8)Tj
9.843 0 0 9.843 435.7983 374.4566 Tm
[(This)-506.6(conrmed)-501.8(the)-505.7(lack)-507.9(of)]TJ
-12.6944 -1.1174 TD
[(evidence)-272.8(available)-274.1(and)-275.2(informed)-270.5(the)-275.3(design)-272.7(of)-267.1(the)-275.3(study)-270.4(and)]TJ
0 -1.1116 TD
[(the)-281.1(methods)-280.8(used)-281.8(for)-279.7(data)-283.3(collection.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 310.8472 330.5763 Tm
[(Phase)-333.1(1.)-330.4(Stage)-337.2(3.)-330.4(Development)-334.5(of)-336.7(the)-334.8(core)]TJ
0 -1.2203 TD
[(and)-329.4(module)-338.8(data)-332.9(collection)-333.6(methods)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 303.1936 Tm
[(The)-380(study)-379.8(design)-382.1(included)-385.8(a)-376.6(core)-386.8(tool,)-382.5(which)-382.1(was)-379.5(com-)]TJ
-1.0137 -1.1174 TD
[(pleted)-343.3(on)-342(all)-344.5(patients)-339.6(irrespective)-352.1(of)-342(the)-338.7(type)-345.5(of)-342(study.)-342.9(Ad-)]TJ
0 -1.1116 TD
[(ditional)-551.9(tools)-547(were)-554.7(developed)-549.2(for)-550.4(use)-551.4(in)-549.5(more)-553.9(complex)]TJ
T*
[(projects.)-233.5(The)-230.3(outline)-233.9(of)-226.8(the)-235(tools,)-227.9(the)-235(methods)-228.9(of)-232.6(use,)-232.3(and)-229.1(the)]TJ
0 -1.1174 TD
[(data)-283.3(they)-276.4(provid)-6.7(e)-278.7(are)-282.1(outlined)-281.1(in)-278.8(Table)-285.6(4.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 310.8472 237.3731 Tm
[(Development)-334.5(of)-330.4(the)-334.8(core)-332.9(tool)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 220.9322 Tm
[(The)-287.9(development)-293.6(of)-290.2(the)-286.8(core)-288.9(tool)-292.7(followed)-287.5(a)-290.2(consultative)]TJ
-1.0137 -1.1116 TD
[(approach)-375.1(with)-374.2(an)-377.7(International)-375.4(expert)-377.7(panel)-376.6(and)-373.1(eight)-375.6(par-)]TJ
T*
[(ticipating)-474.8(NLFs.)-470.3(The)-472.2(resulting)-472(core)-473.2(tool)-465.4(had)-471(13)-474.5(domains)]TJ
0 -1.1174 TD
[(\(Table)-442.2(5\).)-437.6(The)-443.4(initial)-441.5(questions)-442.9(were)-445.3(generated)-440.9(within)-445.6(an)]TJ
0 -1.1116 TD
[(international)-634.7(conference)-638.8(\(4th)-632.3(International)-640.3(Lymphedema)]TJ
T*
[(Framework)-204.2(Conference,)-210.2(June)-201.2(2012,)-203.7(Montpellier,)-209.3(France\))-206.8(and)]TJ
T*
[(the)-200.4(questions)-201(ranked)-199(in)-198.2(order)-202.4(of)-198(importance.)-203.7(The)-201.5(tool)-200.5(initially)]TJ
0 -1.1174 TD
[(included)-207.2(21)-209.5(domains)-205.9(but)-210.8(this)-206.1(was)-212.5(reduced)-207(to)-209.7(13)-203.8(following)-212.7(the)]TJ
0 -1.1116 TD
[(consultation)-280.8(process.)]TJ
1.0137 -1.1116 TD
-.0215 Tc
[(The)-461.5(q)-5.3(ues)-5.1(t).3(i)-5.4(ons)-465.9(cov)-5.3(e)-.7(r)-5.3(e)-.7(d)-460.3(t)-5.4(he)-461.5(mo)-5.3(st)-466.2(ess)-5.1(e)-.7(nt)-5.5(ial)-466.2(i).3(n)-5.3(f).5(or)-5.3(mat)-5.5(i).3(on)-466.1(re-)]TJ
-1.0137 -1.1174 TD
-.0218 Tc
[(qui)-5.7(re)-6.8(d)-345.4(t)0(o)-345.4(u)-5.6(nde)-6.8(rst)-5.7(a)-1(n)-5.6(d)-345.4(the)-346.6(p)-5.6(re)-6.8(val)-5.7(e)-1(nc)-6.8(e)-346.6(o).1(f)-345.4(c)-6.8(hro)-5.6(n).1(ic)-352.4(edem)-6.8(a)-346.6(a)-1(nd)-351.2(its)]TJ
0 -1.1116 TD
-.0215 Tc
[(imp)-5.3(act)-397.1(on)-397(hea)-6.5(lth)-397(se)-6.5(rvi)-5.4(ces)-5.1(.)-393.6(T)-.7(h)-5.3(e)-392.4(to)-5.3(ol)-397.1(was)-396.8(s).6(i)-5.4(m)-.8(pl)-5.5(e)-392.4(a)-.7(n)-5.3(d)-391.2(r)-5.3(a)-.7(pi)-5.4(d)-391.2(t).3(o)]TJ
T*
-.0205 Tc
[(com)-5.5(p)1.4(le)-5.5(te.)-340.7(T).2(ranslation)-344.1(and)-338.4(b)-4.3(ack)-338.4(transla)-5.5(t)1.3(ion)-338.4(o)1.4(f)-338.3(t)-4.5(he)-339.5(core)-339.5(wound)]TJ
0 -1.1174 TD
-.02 Tc
[(and)-418.5(s)-3.6(welling)-412.8(t)-3.9(ools)-412.6(h)-3.8(ave)-419.7(b)1.9(e)-5(e).8(n)-418.5(undertake)-5(n)-412.8(i)-3.9(n)-412.8(D)-4.7(anish,)-415.1(Frenc)-5(h)1.9(,)]TJ
0 -1.1116 TD
-.0216 Tc
[(Tur)-5.4(k).3(i)-5.5(s).5(h,)-491.6(Ita)-6.6(l).2(i)-5.5(a)-.8(n,)-491.6(and)-489.2(J)-5.2(apa)-6.6(n).3(es)-5.2(e)-484.6(t)-5.5(hus)-489(a)-6.6(ddi)-5.6(ng)-489.2(an)-5.4(oth)-5.4(e)-.8(r)-489.2(l).2(e)-6.6(v).3(el)-489.4(of)]TJ
T*
[(val)-5.6(i).1(d)-5.5(a)-.9(ti)-5.6(on.)]TJ
ET
59.754 236.013 239.131 .22676 re
f
59.754 56.58 239.131 .22678 re
f
59.754 217.304 239.131 .28342 re
f
59.754 126.425 239.131 .22675 re
f
59.754 105.222 239.131 .28348 re
f
BT
/F8 1 Tf
9.845 0 0 9.845 82.0346 241.6818 Tm
0 Tc
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(3.)Tj
/F8 1 Tf
1.2496 0 TD
[(Inclusion)-340.5(and)-332(Exclusion)-334.5(Criteria)]TJ
/F11 1 Tf
-6.5129 -1.8427 TD
[(Inclusion)-338.5(criteria)]TJ
/F4 1 Tf
1.002 -1.8946 TD
[(All)-332.4(ages)-340.1(\(data)-335.7(on)-330.2(children)-338.9(only)-332.4(available)-336.6(from)-333.4(specialist)]TJ
.9847 -1.0135 TD
(services\).)Tj
-.9847 -1.0135 TD
[(Has)-333(chronic)-337.7(edema)-337.9(of)-330.2(longer)-335.5(than)-333.5(3)-335(months.)]TJ
T*
[(Is)-335.8(able)-334.7(to)-330.4(understand)-340.5(the)-332.6(study)-333.2(as)-337(set)-332.4(out)-331.4(in)-336.2(the)]TJ
.9847 -1.0077 TD
[(information)-336.2(sheet.)]TJ
-.9847 -1.0135 TD
[(Is)-335.8(able)-334.7(to)-330.4(give)-333.5(informed)-338.7(consent,)-335.1(that)-333.7(is,)]TJ
/F11 1 Tf
16.9877 0 TD
[(\(gives)-336.5(explicit)]TJ
-16.003 -1.0135 TD
[(consent)-331.7(for)-337(their)-334.5(data)-332.4(to)-336.2(be)-331.4(transferred)-341.1(into)-332.5(an)]TJ
0 -1.0077 TD
[(international)-337.2(data)-332.4(base\).)]TJ
-1.9867 -2.4071 TD
[(Exclusion)-340.8(criteria)]TJ
/F4 1 Tf
1.002 -1.8946 TD
[(Is)-312.8(unwilling)-309.9(or)-307.2(unable)-313.7(to)-307.4(participate)-315.7(for)-308.2(whatever)-311.9(reason.)]TJ
0 -1.0135 TD
[(Is)-335.8(receiving)-335.2(end-of-life)-336.1(care.)]TJ
T*
[(When)-335.5(considered)-335.9(to)-336.2(not)-331.4(be)-331.4(in)-336.2(the)-332.6(patients)-339.8(best)-333.4(interest)]TJ
.9847 -1.0077 TD
[(\(decided)-334.1(by)-336(the)-332.6(lead)-334.7(clinician)-335.6(managing)-339.8(their)-334.7(care\).)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(LIMPRINTMETHODS)-344.1(AND)-330.9(VALIDATION)]TJ
53.0113 0 TD
(129)Tj
ET
endstream
endobj
47 0 obj
<>stream
/GS1 gs
BT
/F7 1 Tf
8.9663 0 0 8.9663 62.022 276.4913 Tm
0 0 0 rg
0 Tc
0 Tw
[(Data)-337.7(elds)-333.6(within)-331.6(the)-334.8(core)-332.9(tool)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 260.0503 Tm
[(Th)19.6(e)-180.8(c)0(o)19.7(r)0(e)-170.4(t)0(o)20.7(o)0(l)-169.4(i)0(d)20.7(e)0(n)19.7(t)0(i)20.6()0(e)19.8(d)-179.6(ke)19.7(y)-179.6(i)0(n)20.7(f)0(o)20.9(r)0(m)19.6(a)0(t)19.6(i)0(o)15(n)-173.9(ab)13.9(ou)20.8(t)-179.8(a)0(c)18.5(c)0(e)18.5(s)0(s)-168.8(t)0(o)-169.4(c)0(a)18.5(r)0(e)]TJ
-1.0137 -1.1174 TD
[(an)19.7(d)-335.2(t)0(h)20.7(e)-330.6(ty)20.7(pe)19.7(s)-335(o)0(f)-318.9(t)0(r)15(e)0(a)18.5(t)0(m)19.5(e)0(n)19.7(t)0(.)-321.4(T)0(h)19.6(i)0(s)-318.9(i)0(n)20.7(c)0(l)13.8(u)0(d)20.8(e)0(d)-320.1(w)0(h)20(e)0(t)19.5(h)0(e)19.7(r)-335.1(an)19.7(y)-329.4(t)0(r)15(e)0(a)18.5(t)0(-)]TJ
0 -1.1116 TD
[(me)18.4(nt)-324.9(wa)18.8(s)-335(b)0(e)19.7(i)0(n)15(g)-335.2(gi)20.7(ve)19.7(n)-335.2(o)0(r)-324.7(n)0(o)20.8(t)0(.)-327.2(F)0(o)21(r)-335.1(th)20.7(os)21(e)-336.3(r)0(e)19.7(c)0(e)18.5(i)0(v)15(i)0(n)20.7(g)-335.2(tr)20.7(ea)18.5(tm)19.5(en)19.7(t,)]TJ
T*
[(da)19.7(ta)-256.9(we)18.8(re)-256.8(co)19.7(ll)20.6(ec)18.5(te)19.5(d)-266(o)0(n)-255.6(t)0(h)20.7(e)-267.2(el)19.5(em)18.5(en)19.7(ts)-255.6(of)-255.6(co)19.7(mp)19.6(le)19.6(x)-266(d)0(e)19.7(c)0(o)19.7(n)0(g)20.8(e)0(s)14.1(t)0(i)20.6(v)0(e)]TJ
T*
[(th)20.7(er)19.7(ap)19.7(y:)-301.8(sk)15.3(in)-301.8(ca)18.5(re)19.7(,)-308.7(e)0(x)19.7(e)0(r)14(c)0(i)19.5(s)0(e)19.9(,)-308.7(ma)18.4(nu)20.8(al)-303(ly)15(m)15(p)0(h)15.1(a)0(t)19.5(i)0(c)-303(d)0(r)20.9(a)0(i)19.5(n)0(a)19.7(g)0(e)19.7(,)-314.5(an)19.7(d)]TJ
0 -1.1174 TD
[(ty)20.7(pe)19.7(s)-358(o)0(f)-342(c)0(o)19.7(m)0(p)19.6(r)0(e)19.7(s)0(s)21.2(i)0(o)15(n)0(.)-338.6(O)0(t)14.1(h)0(e)19.7(r)-352.4(tr)20.7(ea)18.5(tm)19.5(en)19.7(ts)-342(no)15.1(te)19.6(d)-352.4(i)0(n)20.7(c)0(l)19.5(u)0(d)20.8(e)0(d)-343.2(a)0(n)13.9(t)0(i)20.6(-)]TJ
25.504 7.1766 TD
[(bi)14.9(ot)20.7(ic)19.6(s,)-211.7(ps)21(yc)19.7(ho)20.8(lo)20.7(gi)14.9(ca)18.5(l)-220.1(s)0(u)21(p)0(p)20.8(o)0(r)20.9(t)0(,)-212(a)0(n)19.7(d)-220(su)15.3(rg)20.9(ic)19.6(al)-210.8(tr)20.7(ea)18.5(tm)19.5(en)19.7(ts)-215.2(su)21(ch)-210.7(as)]TJ
0 -1.1174 TD
[(li)14.8(po)20.8(su)21(ct)19.5(io)20.7(n.)]TJ
1.0137 -1.1116 TD
[(A)-186.3(body)-177.2(map)-184.2(was)-183.7(used)-183.9(to)-186.6(record)-181.7(the)-183.1(sites)-185.1(of)-180.7(swelling)-189.6(and)-183(the)]TJ
-1.0137 -1.1116 TD
[(presence)-358.8(and)-355.8(nature)-360.4(of)-353.5(any)-355.8(concurrent)-354.4(wounds.)-356.3(Lower)-360(and)]TJ
0 -1.1174 TD
[(upper)-398.3(mobility)-396.5(status)-393.5(was)-396.8(dened)-394.7(using)-391.3(a)-393.9(previously)-398.1(pub-)]TJ
0 -1.1116 TD
[(lished)-382.2(classication.)]TJ
7.3823 0 0 6.5614 394.4692 225.411 Tm
(9)Tj
9.843 0 0 9.843 401.8959 221.0456 Tm
[(Information)-377.5(about)-381.2(the)-379(history)-382.1(of)-382.3(cel-)]TJ
-9.0255 -1.1116 TD
[(luliti)-7.3(s)-565.4(and)-563.2(its)-567.8(treatment)-573.7(was)-569.6(recorded,)-568.6(including)-564.4(use)-568.7(of)]TJ
0 -1.1174 TD
[(antibiotics)-383.5(and)-378.8(episodes)-379.5(requiring)-379.9(hospitalization.)-381.1(A)-376.4(WHO)]TJ
0 -1.1116 TD
[(general)-368.4(category)-363.7(of)-365(weight)-360.2(was)-362.2(adopted)-367.3(due)-361.6(to)-359.4(the)-361.7(lack)-364(of)]TJ
T*
[(available)-314.5(BMI)-310.5(for)-308.5(many,)-309.7(particularly)-316.7(those)-306.1(seen)-311.8(in)-307.6(commu-)]TJ
T*
[(nity)-482.7(settings.)]TJ
7.3823 0 0 6.5614 365.7826 170.6456 Tm
(10)Tj
9.843 0 0 9.843 377.9149 166.2803 Tm
[(Important)-484.8(comorbidities)-484.7(linked)-480.3(to)-480.4(chronic)]TJ
-6.5891 -1.1174 TD
[(edem)-8(a)-278.7(were)-284(also)-282(recorded.)]TJ
1.0137 -1.1116 TD
[(The)-437.6(teams)-441(screening)-439.5(the)-436.6(patient)-436.6(were)-439.6(asked)-439.6(to)-434.3(make)-439.9(a)]TJ
-1.0137 -1.1116 TD
[(subjective)-435.2(judgment)-431.9(about)-433(whether)-431.5(the)-430.8(swelling)-437.3(was)-431.4(con-)]TJ
0 -1.1174 TD
[(trolled)-210.8(or)-203.8(not.)-202.7(While)-205(it)-204(is)-203.7(recognized)-205.8(that)-207.4(this)-206.1(question)-205.9(is)-203.7(open)]TJ
0 -1.1116 TD
[(to)-319.1(professional)-314.9(interpretation,)-322.4(nevertheless)-317.2(this)-315.5(is)-313.2(an)-314.4(impor-)]TJ
T*
[(tant)-242(issue)-248.3(that)-242(has)-240.4(previously)-242.6(been)-242.9(linked)-244.2(to)-238.5(whether)-241.4(patients)]TJ
0 -1.1174 TD
[(are)-287.8(accessing)-285(treatment.)]TJ
7.3823 0 0 6.5614 408.4156 93.9401 Tm
(3)Tj
9.843 0 0 9.843 323.0361 78.5763 Tm
[(Further)-256.4(questions)-258.6(examined)-255.6(whether)-258.7(chronic)-257.8(edema)-257.9(was)-252.8(a)]TJ
-1.0137 -1.1116 TD
[(factor)-285.5(in)-273(determining)-281(or)-278.6(delaying)-282.1(discharge)-278.3(from)-282(hospital)-275.1(or)]TJ
0 -1.1174 TD
[(was)-252.8(a)-244.2(reason)-250.6(for)-245.1(long-term)-248.6(community)-249.9(care.)-253.2(Issues)-249.1(of)-244.1(access)]TJ
ET
62.022 719.49 490.167 .22668 re
f
62.022 320.372 490.167 .22678 re
f
62.022 700.781 490.167 .22681 re
f
BT
/F8 1 Tf
9.845 0 0 9.845 202.1669 725.1588 Tm
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(4.)Tj
/F8 1 Tf
1.2496 0 TD
[(Tools,)-331.4(Methods,)-334.2(and)-337.8(Data)-332.7(Delivered)]TJ
/F11 1 Tf
-18.4849 -1.8427 TD
[(Tool)-22761.7(Method)-12343.1(Deliverables)]TJ
/F4 1 Tf
0 -1.9003 TD
[(Core)-334.4(tool)]TJ
18.0242 -1.0077 TD
[(Questionnaire)-334.3(completed)]TJ
.9905 -1.0135 TD
[(by)-330.2(health)-336.9(care)-335.7(professionals)]TJ
16.3197 1.0135 TD
[(Prole)-335.2(of)-336(patients)-333.1(with)]TJ
.9962 -1.0135 TD
[(chronic)-331.9(edema)]TJ
-35.3287 1.0135 TD
[(Core)-334.4(case)-335.5(ascertainment)-337(questionnaire.)]TJ
17.0223 -2.027 TD
[(Chronic)-331.7(edema)-337.9(conrmed)]TJ
.9905 -1.0077 TD
[(by)-330.2(pitting)-335.9(test)-333.6(and)-338.1(conrmation)]TJ
0 -1.0135 TD
[(of)-336(history)-329.6(of)-336(chronic)]TJ
T*
(edema)Tj
/F5 1 Tf
2.9599 0 TD
(>)Tj
/F4 1 Tf
.5528 0 TD
[(3)-329.2(months)]TJ
12.807 3.0348 TD
(Age/gender/duration)Tj
.9962 -1.0077 TD
[(and)-332.4(site)-333.6(of)-336(chronic)-331.9(edema)]TJ
-35.3287 1.0077 TD
[(Identication)-333.6(of)-336(patients)-333.1(with)-339.1(chronic)]TJ
.9847 -1.0077 TD
[(edema)-332.1(in)-336.2(health)-336.9(care)-335.7(systems)]TJ
33.3477 -1.0135 TD
[(Subjective)-336.2(control)-336.7(of)-336(swelling)]TJ
-34.3324 -3.0347 TD
[(Used)-334(in)-330.4(all)-338.5(studies)]TJ
34.3324 2.0213 TD
[(Level)-336.9(of)-336(obesity)]TJ
0 -1.0135 TD
(Mobility)Tj
0 -1.0077 TD
[(Relevant)-341(comorbidities)]TJ
0 -1.0135 TD
[(Classication)-340(of)-336(cause)]TJ
.9962 -1.0135 TD
[(of)-330.2(chronic)-337.7(edema)]TJ
-.9962 -1.0135 TD
[(Previous)-337.2(treatment)]TJ
0 -1.0077 TD
[(Cellulitis)-341.2(history)]TJ
0 -1.0135 TD
[(Presence)-340.5(of)-330.2(a)-336.2(wound)]TJ
T*
[(Access)-338.2(to)-336.2(treatment)]TJ
-35.3344 -2.3265 TD
[(Module)-336.3(tools)]TJ
18.0242 -1.0135 TD
[(Data)-335.5(were)-335.4(gathered)-334.1(from)-333.4(patients)-338.9(using)]TJ
.9905 -1.0077 TD
[(clinical)-334.6(assessment)-342.3(and)-332.4(interviews,)]TJ
0 -1.0135 TD
[(either)-336.9(by)-330.2(self-completion)-342.5(or)]TJ
T*
[(completion)-336.4(by)-330.2(a)-336.2(health)-336.9(professional.)]TJ
16.3197 3.0348 TD
[(The)-339.3(Module)-330.6(Tools)-334.4(collected)]TJ
.9962 -1.0077 TD
[(data)-334.7(that)-333.7(looked)-335.5(in)-330.4(more)]TJ
0 -1.0135 TD
[(depth)-334.5(at)-331.6(factors)-337.5(affecting)]TJ
T*
[(the)-332.6(life)-333.7(of)-336(the)-332.6(patient)]TJ
T*
[(as)-331.2(well)-334.5(as)-337(care)-335.7(delivery,)]TJ
0 -1.0077 TD
[(such)-333.2(as)-331.2(the)-338.3(impact)-332.3(on)]TJ
0 -1.0135 TD
[(discharge)-334.9(from)-333.4(hospital)]TJ
T*
[(or)-330.2(accessing)-341.7(appropriate)-331.5(care,)]TJ
T*
(including:)Tj
-35.3287 8.0965 TD
[(Assessment)-336.2(of)-336(functional)-335.2(impact.)]TJ
35.3344 -9.1043 TD
[(Personal)-338.3(details,)-335.5(including)]TJ
.9847 -1.0135 TD
[(living)-334.7(status,)-333(educational)]TJ
T*
[(attainment,)-335.4(employment)-337.4(status)]TJ
-35.3229 6.0753 TD
[(Demographics)-339.9(and)-332.4(Disability)]TJ
.979 -1.0135 TD
[(assessment)-336.5(\(WHODAS)-334.7(2.0\))]TJ
33.3592 -6.0695 TD
[(Details)-338.7(of)-330.2(swelling)]TJ
-34.3382 5.056 TD
[(Quality-of-life)-341.4(assessment)]TJ
.979 -1.0135 TD
(\(LYMQOL)Tj
/F5 1 Tf
4.6011 0 TD
(+)Tj
/F4 1 Tf
.5528 0 TD
(EQ-5D)Tj
/F5 1 Tf
2.885 0 TD
(+)Tj
/F4 1 Tf
.8868 0 TD
(LFSQQ\))Tj
24.4335 -5.056 TD
[(Mobility)-331.9(status)]TJ
-34.3382 4.0483 TD
[(Details)-338.7(of)-336(swelling)]TJ
34.3382 -5.0618 TD
[(Quality)-337.7(of)-330.2(life)]TJ
-34.3382 4.0483 TD
[(Wound)-335.3(assessment)]TJ
34.3382 -5.0618 TD
[(Impact)-337.9(of)-330.2(cancer)]TJ
-34.3382 4.0483 TD
[(Cancer)-338.7(details)]TJ
34.3382 -5.056 TD
[(Type)-334.5(and)-332.4(impact)-338(of)-336(wound)]TJ
0 -1.0135 TD
[(Factors)-337.3(affecting)-335.3(delivery)]TJ
.9847 -1.0135 TD
[(of)-330.2(care)-335.7(and)-338.1(discharge)]TJ
-.9847 -1.0135 TD
[(Resource)-334.7(use)]TJ
ET
62.022 162.879 239.074 .22676 re
f
62.022 56.92 239.074 .22675 re
f
BT
/F8 1 Tf
9.845 0 0 9.845 91.4456 168.548 Tm
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(5.)Tj
/F8 1 Tf
1.2496 0 TD
[(The)-339.3(domains)-331(of)-337(the)-332.4(Core)-333(Tool)]TJ
/F4 1 Tf
-7.2385 -1.5894 TD
[(1.)-332.6(Type)-334.5(of)-336(facility)-333.4(in)-336.2(which)]TJ
.9905 -1.0135 TD
[(data)-334.7(are)-339.3(collected)]TJ
13.6247 1.0135 TD
[(2.)-332.6(Demographics)]TJ
-14.6152 -2.027 TD
[(3.)-332.6(Level)-336.9(of)-336(obesity)-6843.7(4.)-332.6(Mobility)]TJ
0 -1.0077 TD
[(5.)-332.6(Relevant)-341(comorbidities)-4105.5(6.)-332.6(Classication)]TJ
15.6057 -1.0135 TD
[(of)-336(lymphedema)]TJ
-15.6057 -1.0135 TD
[(7.)-332.6(Lymphedema)-339.4(history)-4896.1(8.)-332.6(Cellulitis)-335.4(History)]TJ
T*
[(9.)-332.6(Categories)-337.1(of)-336(treatment)-3941.4(10.)-333.6(Site)-333.5(of)-336(swelling)]TJ
0 -1.0077 TD
[(11.)-333.6(Wound)-335.3(area)-8075.2(12.)-333.6(Access)-338.2(to)-330.4(treatment)]TJ
0 -1.0135 TD
[(13.)-333.6(Subjective)-336.2(control)]TJ
.9905 -1.0135 TD
[(of)-336(swelling)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(130)Tj
46.3153 0 TD
[(MOFFATT)-333.6(ET)-338.7(AL.)]TJ
ET
endstream
endobj
51 0 obj
<>stream
0 0 0 rg
/GS1 gs
310.847 113.102 239.074 .22675 re
f
310.847 56.976 239.074 .22684 re
f
BT
/F4 1 Tf
9.843 0 0 9.843 59.7543 616.762 Tm
0 Tc
0 Tw
[(to)-359.4(specialist)-366(treatment)-366.3(and)-355.8(the)-361.7(distance)-363.7(from)-362.7(services)-363.3(were)]TJ
0 -1.1174 TD
[(also)-282(recorded.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 578.0408 Tm
[(Expert)-334.4(review)-339(of)-330.4(the)-334.8(core)-332.9(tool)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 561.5999 Tm
[(Each)-359.3(of)-353.5(the)-355.9(8)-352.4(participating)-358.2(frameworks)-355(engaged)-356.8(10)-353.5(pro-)]TJ
-1.0137 -1.1116 TD
[(fessionals)-231.9(\(generalists)-224(and)-223.3(specialists\))-229.7(to)-221.2(review)-228.8(the)-223.5(core)-225.6(tool)]TJ
T*
[(using)-195.5(a)-198.1(set)-194.5(of)-192.2(5)-191.2(validated)-198.1(case)-197.8(studies)-193.1(to)-198.2(complete)-198.1(the)-194.7(tool)-189(and)]TJ
0 -1.1174 TD
[(decide)-240.6(the)-240.7(classication.)-241.2(Data)-238.1(were)-243.7(entered)-235.9(into)-240.8(the)-235(database)]TJ
0 -1.1116 TD
[(and)-476.8(the)-476.9(results)-475.2(were)-474.1(compared)-480(by)-474.5(ve)-470.8(independen)-8.9(t)-473.5(lym-)]TJ
T*
[(phologists)-270.2(for)-268.2(accuracy)-273.8(of)-272.9(classication)-272.4(and)-269.4(data)-271.8(quality.)-266.1(Of)]TJ
0 -1.1174 TD
[(the)-499.9(400)-492.9(complete)-497.6(case)-503(reviews,)-498.1(correct)-500.8(classication)-497(oc-)]TJ
0 -1.1116 TD
[(curred)-198.9(in)-198.2(387/400)-197.9(\(97%\).)-200(The)-195.7(13)-198(cases)-198.7(in)-198.2(which)-197.7(classication)]TJ
T*
[(differed)-345.2(related)-339.7(to)-342.1(the)-338.7(decision)-345.3(about)-340.9(whether)-339.3(the)-338.7(case)-341.8(was)]TJ
0 -1.1174 TD
[(due)-401.9(to)-399.7(primary)-401.8(or)-399.6(secondary)-404.8(lymphedema.)-400.7(This)-403(is)-399.5(a)-399.7(well-)]TJ
0 -1.1116 TD
[(known)-282.8(and)-280.9(valid)-283.4(difculty)-282(for)-279.7(clinicians.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 422.4755 Tm
[(Module)-338.8(tools)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 406.0345 Tm
[(The)-489.5(Module)-486.9(Tools)-490.5(aimed)-487.2(to)-486.1(assess)-492(the)-488.4(functional)-486(and)]TJ
-1.0137 -1.1116 TD
[(quality-of-life)-365(impact)-356(using)-356.8(validated)-359.4(tools)-356.9(where)-360(possible.)]TJ
T*
[(Further)-509.9(clinical)-513.9(information)-510.2(about)-513.7(wounds)-508.4(and)-511.3(treatment)]TJ
0 -1.1174 TD
[(\(where)-315(present\))-316.3(and)-309.7(details)-309.7(of)-313.2(the)-309.9(severity)-316.4(of)-307.4(swelling)-316.3(were)]TJ
0 -1.1116 TD
[(included.)-285.5(Module)-279.5(Tools)-283.1(covered)-281.9(the)-286.8(following)-281.9(areas:)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 332.674 Tm
[(Demographics)-338.9(and)-329.4(disability)-338.8(\(WHODAS)-336.8(2.0\))]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 316.233 Tm
[(This)-322.3(well-validated)-326.8(tool)-321.4(included)-322.4(questions)-322(that)-322.6(explored)]TJ
-1.0137 -1.1116 TD
[(the)-384.7(patients)-381(personal)-385.4(circumstances)-384.1(for)-383.4(example,)-384.6(housing,)]TJ
T*
[(employment,)-514.8(and)-505.6(education.)-512.4(WHODAS)-513.3(2.0)-506.7(is)-503.2(a)-509.1(12-item)]TJ
0 -1.1174 TD
[(disability)-283.3(assessment)-285.8(schedule)-288.7(completed)-279.8(by)-284.4(the)-281.1(patient.)]TJ
7.3823 0 0 6.5614 284.0881 287.7165 Tm
(11)Tj
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 253.8141 Tm
[(Quality)-337.7(of)-330.4(life)-337(\(LYMQOL)-332.7(and)-335.7(EQ-5D)-332.8(and)-335.7(LFSQQ\))]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 237.3731 Tm
[(Quality)-206(of)-209.5(life)-201.6(was)-206.7(assessed)-213.1(with)-201.4(a)-209.6(combination)-206.1(of)-203.8(disease-)]TJ
-1.0137 -1.1116 TD
[(specic)-287.4(and)-280.9(generic)-282(tools.)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 69.7323 211.2944 Tm
()Tj
/F11 1 Tf
9.843 0 0 9.843 78.633 209.9905 Tm
(LYMQOL)Tj
/F4 1 Tf
4.1758 0 TD
[(is)-232.5(a)-238.4(v)0(a)13.9(l)0(i)20.6(d)0(a)19.7(t)0(e)19.6(d)-243(co)19.7(nd)20.8(it)20.6(io)20.7(n-)15.1(sp)21(ec)18.5(i)20.9(c)-244.2(q)0(u)20.8(a)0(l)19.5(i)0(t)20.6(y)0(-)20.9(o)0(f)15.1(-)0(l)20.7(i)0(f)20.7(e)]TJ
-4.1758 -1.1116 TD
[(as)19.9(se)19.9(ss)15.5(me)18.4(nt)-480.4(in)20.7(st)20.9(ru)15.1(m)15(e)0(n)13.9(t)-485(\(i)15(t)-490.8(i)0(s)-480.2(n)0(o)20.8(t)-490.8(sp)21(ec)18.5(i)20.9(ca)18.5(ll)14.8(y)-484.9(v)0(a)13.9(l)0(i)20.6(d)0(a)19.7(t)0(e)19.5(d)]TJ
0 -1.1174 TD
[(fo)20.9(r)-421.5(p)0(a)19.7(t)0(i)14.8(e)0(n)19.7(t)0(s)-411.1(w)0(i)19.8(t)0(h)-411.3(l)0(y)20.7(m)0(p)19.6(h)0(a)13.9(t)0(i)20.6(c)-422.7(l)20.9(ar)19.7(ia)19.6(si)15.1(s\))-410.9(th)20.7(at)-412.4(as)19.9(se)19.9(ss)15.5(es)-412.1(th)20.7(e)]TJ
0 -1.1116 TD
[(im)19.5(pa)19.7(ct)-320.3(of)-313.2(ly)15(m)15(p)0(h)15.1(e)0(d)19.7(e)0(m)18.5(a)-324.8(on)-319(th)20.7(e)-324.8(p)0(a)19.7(t)0(i)14.8(e)0(n)19.7(t)0()20.7(s)-329.2(ev)19.7(er)19.7(yd)20.8(ay)-320.1(li)20.6(vi)20.7(ng)]TJ
T*
[(an)19.7(d)-387(h)0(e)19.7(a)0(l)19.5(t)0(h)15(-)0(r)20.9(e)0(l)19.6(a)0(t)19.5(e)0(d)-377.7(q)0(u)20.8(a)0(l)13.8(i)0(t)20.6(y)-387(of)-376.5(li)20.6(fe)19.7(.)-389.3(T)0(h)19.6(e)-388.2(to)20.7(ol)-376.7(is)-376.5(va)13.9(li)20.6(da)19.7(te)19.5(d)]TJ
T*
[(fo)20.9(r)-323.6(l)0(o)20.7(w)0(e)13(r)-323.6(an)19.7(d)-323.6(u)0(p)20.8(p)0(e)19.7(r)-323.6(li)20.6(mb)19.6(s.)]TJ
7.3823 0 0 6.5614 184.6488 159.5905 Tm
(12)Tj
/F9 1 Tf
7.9702 0 0 7.9702 69.7323 145.5307 Tm
()Tj
/F11 1 Tf
9.843 0 0 9.843 78.633 144.2267 Tm
(EQ-5D)Tj
/F4 1 Tf
3.26 0 TD
[(is)-376.5(a)-376.6(generic)-374.2(quality-of-l)-9(ife)-373.2(instrument)-376.4(applica-)]TJ
-3.26 -1.1116 TD
[(ble)-292.6(to)-296.1(a)-290.2(wide)-294.6(range)-295.8(of)-295.9(health)-291.4(conditions)-294.6(and)-298.2(provides)-292.1(a)]TJ
T*
[(simple)-469.8(descriptive)-470.8(prole)-462.7(and)-471(single)-468.6(index)-461.8(value)-468.7(for)]TJ
0 -1.1174 TD
[(health)-337.5(status.)]TJ
7.3823 0 0 6.5614 131.0173 115.7102 Tm
(13)Tj
/F9 1 Tf
7.9702 0 0 7.9702 69.7323 101.707 Tm
()Tj
/F11 1 Tf
9.843 0 0 9.843 78.633 100.4031 Tm
-.0159 Tc
[(LFS)-15.9(Q)9.8(Q)-680.2(\().3(L)-15.9(y)9.7(mpha)-15.9(t)10.6(i).2(c)-680.5(F)-.9(i)-15.9(l)10.4(ari)-15.9(a)10.6(sis)-15.9(-)10.9(Speci)-15.9()10.6(c)-680.5(Qu)-15.9(a)10.7(lity)-15.9(-)9.6(o).3(f-L)-15.9(i)10.7(fe)]TJ
0 -1.1116 TD
0 Tc
[(Q)15.3(u)16.2(es)25.6(t)16.1(i)16.1(o)16.2(nn)26.6(a)16.2(i)16.1(r)16.4(e)0(\))]TJ
/F4 1 Tf
6.1859 0 TD
-.016 Tc
[(is)-339.4(a)-335(c)-1(on)-16(d)10.6(itio)-16(n)10.6(-).2(sp)-16(e)9.4(c)-1(ic)-340.8(i).1(nst)-16(r)10.5(ument)-339.8(for)-339.6(pa-)]TJ
-6.1859 -1.1174 TD
[(tie)-15.9(n)9.5(t).2(s)-373.9(w)-.6(ith)-374.1(lym)-15.9(p)9.5(hatic)-375.3(l)-15.9(a)9.4(r).3(ias)-15.9(i)10.8(s.)-370.7(Th)-15.9(e)-359.1(L)-.9(F)-15.9(S)11(QQ)-375(is)-373.9(inte)-15.9(n)9.5(d).3(ed)]TJ
0 -1.1116 TD
-.0157 Tc
[(for)-466(us)-15.7(e)-450.8(f).5(o)-15.7(r)-449.8(p)-15.7(a)9.7(tient)-15.7(s)-449.8(w)-15.7(i)9.9(t).4(hin)-466().6(la)-15.7(r)9.8(i).4(al)-466.2(areas)-465.9(an)-15.7(d)-449.9(t).4(h)-15.7(e)-451(qu)-15.7(e)9.7(s).7(-)]TJ
T*
[(tio)-15.7(n)10.9(n).5(air)-15.7(e)-324.3(was)-333.4(d).5(ev)-15.7(e)9.7(l).4(oped)-339.3(b).5(ased)-333.6(o)-15.7(n)-323.2(an)-333.6(Indi)-15.7(a)9.6(n)-333.6(life)-15.7(s)9.9(tyl)-15.7(e)9.6(.)]TJ
7.3823 0 0 6.5614 286.9794 60.9449 Tm
-.0162 Tc
(14)Tj
/F7 1 Tf
8.9663 0 0 8.9663 310.8472 725.7825 Tm
0 Tc
[(Details)-331.1(of)-336.7(swelling)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 709.3416 Tm
[(This)-235.9(tool)-240.8(provided)-240.5(further)-239.3(details)-240.6(about)-237.2(the)-240.7(swelling.)-239.1(Each)]TJ
-1.0137 -1.1116 TD
[(study)-414.4(site)-420.3(elected)-421.6(one)-413.4(measureme)-11(nt)-411.3(techn)-8(ique,)-412.3(which)-422.4(was)]TJ
0 -1.1174 TD
[(standardized)-282.9(for)-279.7(all)-286.9(patients.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 310.8472 665.5179 Tm
[(Limb)-329.9(circumference)-336.8(and)-335.7(volume)-333.8(measures)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 649.077 Tm
[(St)20.9(an)19.7(da)19.7(rd)20.9(iz)19.5(ed)-418.1(ci)19.6(rc)19.7(um)19.6(fe)19.7(re)19.7(nt)14.9(ia)19.6(l)-421.7(l)0(i)14.8(m)15(b)-427.3(m)0(e)18.4(a)0(s)19.9(u)0(r)15.1(e)0(m)24.2(e)0(n)13.9(t)0(s)-411.1(u)0(s)15.3(i)0(n)20.7(g)-427.3(a)]TJ
-1.0137 -1.1174 TD
[(ta)19.6(pe)-262.6(me)18.4(as)19.9(ur)20.9(e)-273(w)0(e)13(r)0(e)-262.5(t)0(h)20.7(e)-273(mo)19.6(st)-261.3(wi)19.8(de)13.9(ly)-261.5(us)21(ed)-262.5(an)19.7(d)-271.8(a)0(c)18.5(c)0(e)12.8(s)0(s)21.2(i)0(b)20.7(l)0(e)-262.7(t)0(e)19.6(c)0(h)19.7(-)]TJ
0 -1.1116 TD
[(ni)20.7(qu)20.8(e.)-362.8(Up)20(pe)19.7(r)-375.4(a)0(n)19.7(d)-369.7(lo)20.7(we)18.8(r)-369.7(l)0(i)14.8(m)0(b)-360.5(c)0(i)19.5(r)0(c)19.7(u)0(m)19.6(f)0(e)19.7(r)0(e)19.7(n)0(c)19.7(e)-376.6(we)18.8(re)-360.4(me)18.4(as)19.9(ur)20.9(ed)]TJ
T*
[(bi)20.7(la)19.5(te)19.6(ra)19.7(ll)20.6(y)-271.8(a)0(t)-262.7(t)0(w)19.8(o)-271.8(po)20.8(in)20.7(ts)-261.3(ac)18.5(co)19.7(rd)20.9(in)20.7(g)-271.8(t)0(o)-261.5(t)0(h)20.7(e)-273(si)20.9(te)-262.7(of)-255.6(sw)14.4(el)19.5(li)20.6(ng)20.8(:)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 320.485 599.7542 Tm
(B)Tj
/F4 1 Tf
9.843 0 0 9.843 329.7826 599.7542 Tm
.0188 Tc
[(mid-)-5.3(upp)-5.3(er)-592.8(arm)-594.1(\().5(1)-5.3(0)-166.6(cm)-594.1(pr)-5.3(oxim)-6.6(a)-.7(l)-593(t).3(o)-592.8(t).3(he)-594(ol)-5.5(ecr)-5.3(anon)]TJ
T*
.02 Tc
(process\))Tj
/F10 1 Tf
3.9849 0 0 3.9849 320.485 577.814 Tm
0 Tc
(B)Tj
/F4 1 Tf
9.843 0 0 9.843 329.7826 577.814 Tm
[(forearm)-333.7(\(10)-170.3(cm)-332.9(distal)-336.3(to)-330.6(the)-338.7(olecranon)-336(process\))]TJ
/F10 1 Tf
3.9849 0 0 3.9849 320.485 566.8723 Tm
(B)Tj
/F4 1 Tf
9.843 0 0 9.843 329.7826 566.8723 Tm
[(mid-thigh)-334(\(20)-164.5(cm)-338.6(proximal)-334(to)-336.4(the)-332.9(patella\))]TJ
/F10 1 Tf
3.9849 0 0 3.9849 320.485 555.9305 Tm
(B)Tj
/F4 1 Tf
9.843 0 0 9.843 329.7826 555.9305 Tm
[(calf)-335.1(\(20)-164.5(cm)-338.6(distal)-336.3(to)-330.6(the)-332.9(patella\))]TJ
/F7 1 Tf
8.9663 0 0 8.9663 310.8472 533.9904 Tm
[(Limb)-329.9(volume)-333.8(methods)-338.5(\(specialist)-330.9(centers\))]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 517.5494 Tm
[(Limb)-364.1(volume)-366.2(measures)-364.5(were)-370.4(undertaken)-365.9(in)-365.2(centers)-368.2(with)]TJ
-1.0137 -1.1116 TD
[(access)-264.3(to)-261.5(specialist)-268.1(methods.)-261.1(Limb)-266.1(volume)-262.6(was)-264.3(expressed)-266.4(in)]TJ
0 -1.1174 TD
[(milliliters)-308.9(for)-302.7(each)-307.4(limb)-305.4(using)-305(a)-301.8(standard)-310.5(method)-302.9(for)-308.5(all)-304.2(pa-)]TJ
0 -1.1116 TD
[(tients)-486(within)-480.2(the)-488.4(study)-483.5(site.)-481.4(The)-483.7(methods)-488.1(included)-483.7(water)]TJ
T*
[(displacement)-284.3(and)-280.9(Perometry.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 310.8472 446.7967 Tm
[(KaposiStemmer)-331.2(sign)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 430.3558 Tm
[(The)-201.5(KaposiStemmer)-206.4(sign)-200.2(involved)-206.1(pinching)-200.3(a)-203.8(skin)-200.2(fold)-206.1(at)]TJ
-1.0137 -1.1116 TD
[(the)-183.1(base)-185.1(of)-186.5(the)-183.1(second)-187.3(toe)-183.1(or)-180.7(middle)-187.8(nger)-185(of)-186.5(the)-183.1(limb)-184.4(that)-184.4(had)]TJ
T*
(edema.)Tj
7.3823 0 0 6.5614 339.1369 412.8377 Tm
(15)Tj
9.843 0 0 9.843 348.7747 408.4724 Tm
[(The)-230.3(sign)-229(was)-229.8(judged)-226.8(to)-232.7(be)-228(positive)-229(if)-226.9(the)-229.2(skin)-229(could)]TJ
-3.8532 -1.1174 TD
[(not)-216.5(be)-216.5(lifted)-221.2(and)-217.6(negative)-225.7(if)-215.4(the)-217.7(skin)-217.5(could)-219.9(be)-222.2(lifted)-215.5(normally.)]TJ
1.0137 -1.1116 TD
[(Collectively,)-246.5(these)-249.7(data)-243(were)-249.5(used)-247.3(to)-244.2(describe)-248.4(and)-246.4(classify)]TJ
-1.0137 -1.1116 TD
[(severity)-592.9(using)-598.7(the)-592.1(International)-600(Society)-597.6(of)-589.7(Lymphology)]TJ
0 -1.1174 TD
[(staging)-279.6(tool)]TJ
7.3823 0 0 6.5614 357.5054 369.0141 Tm
(1618)Tj
9.843 0 0 9.843 375.9873 364.592 Tm
(:)Tj
/F9 1 Tf
7.9702 0 0 7.9702 320.8251 349.455 Tm
()Tj
/F11 1 Tf
9.843 0 0 9.843 329.6692 348.1511 Tm
[(ISL)-268.1(stage)-265.8(I:)-261.3(Early)-267(onset)-265.8(of)-261.5(the)-263.8(condition,)-268.3(where)-267.9(there)-267(is)]TJ
0 -1.1116 TD
[(accumulation)-402.7(of)-399.7(tissue)-399.3(edema)-400.4(that)-396.3(subsides)-401.2(with)-397.4(limb)]TJ
T*
[(elevation.)-339.8(The)-332.6(edema)-337(may)-339.4(be)-331.7(pitting)-336.5(at)-330.6(this)-338.5(stage.)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 320.8251 316.5731 Tm
()Tj
/F11 1 Tf
9.843 0 0 9.843 329.6692 315.3259 Tm
[(ISL)-625.2(stage)-622.9(II:)-619.5(Limb)-621.5(elevation)-624.3(alone)-623.1(rarely)-619.2(reduces)]TJ
0 -1.1174 TD
[(swelling)-339.5(and)-331.6(pitting)-336.5(is)-336.2(manifested.)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 320.8251 294.6897 Tm
()Tj
/F11 1 Tf
9.843 0 0 9.843 329.6692 293.3858 Tm
[(ISL)-291.1(stage)-283.1(III:)-286.5(The)-286.5(tissue)-289.9(is)-284.4(hard)-286.4(\(brotic\))-287.5(and)-285.5(pitting)-290.5(is)]TJ
0 -1.1116 TD
[(absent.)-581.4(Skin)-575.9(changes)-574.3(such)-575.6(as)-578(thickening,)-577(hyperpig-)]TJ
0 -1.1174 TD
[(mentation,)-298(increased)-289.6(skin)-293.5(folds,)-291.2(fat)-291.5(deposits,)-289.7(and)-291.3(warty)]TJ
0 -1.1116 TD
[(overgrowths)-343.3(develop.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 310.8472 234.5952 Tm
(Wounds)Tj
/F4 1 Tf
9.843 0 0 9.843 320.8251 218.1543 Tm
[(This)-189.8(tool)-194.7(provided)-200.1(data)-196.9(about)-191.1(all)-200.6(wounds,)-195(including)-195.8(type)-195.8(of)]TJ
-1.0137 -1.1116 TD
[(wound,)-574.3(location,)-579.4(severity,)-573.3(wound)-576.6(area,)-575.7(wound)-576.6(duration,)]TJ
0 -1.1174 TD
[(history)-278.4(of)-284.4(infection,)-281(and)-280.9(frequency)-284(of)-278.6(dressing)-286.1(changes.)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 320.8251 181.0771 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 329.6692 179.8298 Tm
(Cancer)Tj
-.8985 -1.1174 TD
[(A)-295.7(specic)-299(tool)-298.4(for)-297(patients)-299.3(whose)-301.1(chronic)-298.1(edema)-304(was)-298.9(the)]TJ
-1.0137 -1.1116 TD
[(consequence)-444(of)-445.7(cancer)-443.2(treatment)-447(or)-445.7(a)-440(direct)-446.9(effect)-442.1(of)-445.7(the)]TJ
T*
[(disease)-281.6(was)-275.9(developed.)-281.9(This)-276.2(was)-281.6(a)-273(14-domain)-283.1(questionnaire)]TJ
0 -1.1174 TD
[(focusing)-441.9(on)-439.9(types)-438.6(of)-439.9(cancer)-449(and)-436.4(surgical)-443.1(and)-442.2(nonsurgical)]TJ
0 -1.1116 TD
[(treatments.)-284.3(The)-282.1(types)-283.1(of)-278.6(cancer)-281.9(included)-287.9(were:)]TJ
9.845 0 0 9.845 310.8472 103.1244 Tm
[(Breast)-16104.4(Cervical)]TJ
0 -1.0077 TD
[(Endometrial)-13698.4(Ovarian)]TJ
0 -1.0135 TD
[(Bladder)-15489.4(Vulval)]TJ
T*
[(Colorectal)-14480.4(Melanoma)]TJ
T*
[(Head)-335.4(and)-332.4(neck)-12542.7(Other)-335.4(cancers)]TJ
ET
59.754 719.49 239.074 .22668 re
f
59.754 643.408 239.074 .22681 re
f
BT
/F8 1 Tf
9.845 0 0 9.845 84.0189 725.1588 Tm
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(6.)Tj
/F8 1 Tf
1.2496 0 TD
[(Classication)-337.8(of)-337(Chronic)-332.7(Edema)]TJ
/F4 1 Tf
-6.7145 -1.5894 TD
[(Primary)-337.5(Lymphedema)]TJ
0 -1.0135 TD
[(Secondary)-340.5(Lymphedema)-5015.3(Cancer)]TJ
15.0989 -1.0135 TD
(Noncancer)Tj
0 -1.0077 TD
[(Contributory)-330.1(factors:)]TJ
.9905 -1.0135 TD
[(venous)-335.2(disease,)]TJ
T*
[(obesity,)-334.1(immobility,)]TJ
T*
[(other)-334.5(\(free)-335.5(text\))]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(LIMPRINTMETHODS)-344.1(AND)-330.9(VALIDATION)]TJ
53.0113 0 TD
(131)Tj
ET
endstream
endobj
55 0 obj
<>stream
/GS1 gs
BT
/F7 1 Tf
8.9663 0 0 8.9663 62.022 484.2708 Tm
0 0 0 rg
0 Tc
0 Tw
[(Phase)-333.1(1.)-336.7(Stage)-330.8(4.)-336.7(Development)-334.5(and)-329.4(validation)]TJ
0 -1.2203 TD
[(of)-336.7(a)-333.2(classication)-332.2(for)-332.5(chronic)-333.8(edema)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 456.8881 Tm
[(A)-261.2(15-member)-262.3(expert)-262.5(panel)-261.4(reviewed)-266.7(and)-257.9(assessed)-264.9(a)-261.4(set)-263.6(of)]TJ
-1.0137 -1.1174 TD
[(eight)-260.4(case)-266.9(studies)-262.2(for)-262.4(content)-263.7(and)-257.9(face)-261.3(validity)-263.9(and)-263.7(to)-261.5(ensure)]TJ
0 -1.1116 TD
[(that)-201.7(they)-207.3(reected)-203.5(the)-206.2(chronic)-206(edema)-200.3(classication)-209(categories)]TJ
T*
[(contained)-295.9(in)-290.3(the)-286.8(core)-294.7(tool.)-290.3(There)-291.2(was)-293.1(a)-290.2(100%)-287.7(response)-292.9(rate.)]TJ
0 -1.1174 TD
[(Five)-195.6(of)-192.2(the)-194.7(eight)-191.2(case)-197.8(studies)-193.1(achieved)-197.9(a)-192.3(90%)-194.4(agreement)-200.2(level)]TJ
0 -1.1116 TD
[(for)-487.1(the)-488.4(classication)-491.2(of)-491.7(lymphedema)-489.4(and)-488.3(these)-485.8(ve)-488.1(case)]TJ
T*
[(studies)-285.2(were)-284(used)-276.1(for)-285.5(the)-281.1(review)-280.6(of)-284.4(the)-281.1(core)-277.4(tool)-281.1(in)-284.5(stage)-278.5(4.)]TJ
1.0137 -1.1116 TD
[(The)-207.3(classication)-214.8(was)-206.7(made)-209.6(on)-203.8(whether)-212.6(the)-206.2(chronic)-211.7(edema)]TJ
-1.0137 -1.1174 TD
[(was)-189.5(of)-186.5(primary)-188.7(origin)-185.4(or)-186.5(due)-188.8(to)-186.6(secondary)-191.7(causes)-188.3(\(Table)-188.8(6\).)-189.9(In)]TJ
0 -1.1116 TD
[(those)-444.3(with)-443.3(a)-440(secondary)-445.2(cause)-440.8(a)-445.8(number)-441(of)-439.9(key)-442.2(suspected)]TJ
T*
[(contributory)-366.1(factors)-367(were)-370.4(included,)-366.2(such)-368.2(as)-366(venous)-364.7(disease)]TJ
0 -1.1174 TD
[(and)-275.2(obesity.)-277.3(During)-278.3(the)-275.3(studies)-279.4(specialist)-279.6(lymphology)-277.5(teams)]TJ
0 -1.1116 TD
[(undertook)-287.6(this)-286.7(classication)-289.6(where)-290.9(patients)-287.8(had)-286.7(been)-289(identi-)]TJ
T*
[(ed)-280.8(and)-280.9(conrmed)-282.9(to)-284.6(have)-277.4(chronic)-286.6(edema.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 62.022 282.5007 Tm
[(Stage)-337.2(5.)-330.4(Interrater)-338.1(reliability)-332.1(studies)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 266.0598 Tm
[(The)-478(LIMPRINT)-480.3(study)-477.7(included)-483.7(a)-474.6(number)-481.3(of)-474.5(interrater)]TJ
-1.0137 -1.1116 TD
[(reliability)-533.6(studies)-527.1(to)-526.5(assess)-532.3(the)-528.7(accuracy)-533(of)-526.3(detection)-532.2(of)]TJ
T*
[(chronic)-229(edema)-229.1(using)-230.1(the)-229.2(pitting)-227.1(test)-230.3(and)-229.1(the)-223.5(other)-231.4(methods)-228.9(of)]TJ
T*
(clarication.)Tj
1.0137 -1.1174 TD
[(Dai)-224.3(et)-216.6(al.)]TJ
7.3823 0 0 6.5614 107.3763 226.6015 Tm
(7)Tj
9.843 0 0 9.843 113.2724 222.2361 Tm
[(undertook)-224.3(a)-221.1(cross-sectional)-228.3(study)-218.5(within)-221(a)-221.1(long-)]TJ
-5.2068 -1.1116 TD
[(term)-340.9(care)-341.9(hospital)-344.2(in)-336.4(Japan.)-339.4(The)-345.5(interrater)-343.1(reliability)-343.5(of)-336.2(the)]TJ
T*
[(pitting)-290.5(test)-293.6(for)-285.5(evaluating)-297.1(edema)-292.5(was)-287.4(tested)-297(for)-285.5(34)-290.2(locations)]TJ
0 -1.1174 TD
[(of)-192.2(the)-194.7(body.)-197.9(The)-195.7(pitting)-192.5(test)-195.7(was)-195.2(applied)-194.6(for)-193.3(10)-198(seconds)-194(with)-195.6(a)]TJ
25.504 54.435 TD
[(similar)-188.8(force)-180.6(to)-180.9(that)-184.4(used)-183.9(by)-180.8(the)-183.1(expert)-181.8(assessor)-188.9(who)-182.7(acted)-181.9(as)-181.7(a)]TJ
0 -1.1174 TD
[()45(gold)-282.1(standard.)-8.7()50.8()-283.3(Detection)-291.1(of)-290.1(the)-286.8(presence)-289.7(of)-290.1(edema)-286.7(on)-284.4(re-)]TJ
0 -1.1116 TD
[(moval)-209.6(of)-209.5(pressure)-212.3(was)-206.7(assessed)-213.1(using)-207(the)-206.2(modied)-211.7(Fukazawa)]TJ
T*
(method)Tj
7.3823 0 0 6.5614 342.7086 696.6423 Tm
(19)Tj
9.843 0 0 9.843 352.8566 692.277 Tm
[(described)-284(in)-284.6(Table)-279.9(7.)]TJ
-3.0296 -1.1116 TD
[(Five)-351.1(bedridden)-352.2(patients)-351.2(were)-353.2(assessed)-351.3(by)-347.8(the)-350.2(gold)-350.1(refer-)]TJ
-1.0137 -1.1174 TD
[(ence)-307.4(and)-298.2(four)-303.8(independent)-303.9(assessors.)-302.7(Agreement)-309.4(among)-301.6(the)]TJ
0 -1.1116 TD
[(assessors)-587.2(was)-575.4(high)-580.5(at)]TJ
/F5 1 Tf
10.0334 0 TD
(>)Tj
/F4 1 Tf
.5529 0 TD
[(0.85)-576.9(with)-581.5(the)-574.8(kappa)-583.8(coefcient)]TJ
-10.5863 -1.1116 TD
[(showin)-7.4(g)-277.6(fair)-282.1(agreement)-286.6(\(range)-279.6(0.510.81\))-280.6(\(Table)-286.7(8\).)]TJ
1.0137 -1.1174 TD
[(The)-403.1(same)-405.2(methodology)-406.4(was)-402.6(used)-402.8(in)-405.5(three)-399.6(U.K.)-408.2(studies.)]TJ
-1.0137 -1.1116 TD
[(Two)-454.6(of)-457.2(the)-453.8(studies)-452.2(involved)-459.5(patients)-454.8(seen)-455.8(by)-451.5(community)]TJ
T*
[(nursing)-387.8(services)-386.4(and)-384.6(one)-384.6(with)-379.9(patients)-385.7(within)-388(a)-382.4(residential)]TJ
0 -1.1174 TD
[(care)-226.7(facility.)-222.4(Results)-217.1(from)-224.4(these)-220.9(studies)-216.1(conrmed)-225.3(a)-215.4(high)-223.4(rate)]TJ
0 -1.1116 TD
[(of)-474.5(detection)-474.6(of)-474.5(chronic)-470.9(edema)-476.8(although)-471(mild)-472.4(edema)-471(was)]TJ
T*
[(missed)-273.7(by)-267.1(a)-267.2(proportion)-264.6(of)-267.1(community)-273(nurses)-266.5(compared)-272.7(with)]TJ
T*
[(the)-286.8(expert)-279.7(assessor.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 313.0582 540.7936 Tm
[(Phase)-339.5(1.)-330.4(Stage)-337.2(6.)-330.4(Construction)-333.6(and)-335.7(testing)]TJ
0 -1.2203 TD
[(of)-336.7(the)-334.8(online)-334.1(database)]TJ
/F1 1 Tf
1.1128 -1.6123 TD
[(Security)-703.9(and)-702.5(international)-701.3(requirements)-702.6(of)-703.5(the)-701.6(online)]TJ
-1.1128 -1.2203 TD
[(data)-263.4(base.)]TJ
/F4 1 Tf
9.843 0 0 9.843 363.5716 504.4534 Tm
[(LIMPRINT)-221.1(data)-214.2(were)-214.9(managed)-214(by)-209.5(an)-216.5(electronic)]TJ
-5.1319 -1.1174 TD
[(data)-415.8(management)-409.9(system)-411.9(that)-409(had)-413.4(a)-405.4(comprehensive)-417.5(set)-407.6(of)]TJ
0 -1.1116 TD
[(securi)-8.8(ty)-474.6(features)-478.7(that)-472.4(included)-477.9(the)-476.9(storage)-476.5(of)-474.5(data)-479.2(in)-474.6(en-)]TJ
T*
[(crypted)-234.8(form)-230.2(and)-229.1(individualized)-232.7(password-controlled)-238.3(access.)]TJ
0 -1.1174 TD
.0114 Tc
[(Th)4.5(e)-278.8(s)4.7(ys)4.7(tem)-273.1(h)-1.2(ad)-277.7(an)-271.9(au)4.5(di)4.4(t)-272.1(t)-1.3(rail)4.4(,)-274.3(w)3.7(hich)-271.9(tr)4.6(acked)-277.7(a)3.4(ll)-272.1(act)4.4(i)-1.3(v)4.5(ity)-271.9(o)4.5(n)]TJ
0 -1.1116 TD
.0118 Tc
[(the)-238.1(s)-.6(y)4.9(s)-.6(tem,)-239.3(i)4.8(n)-.8(cl)4.8(ud)4.9(in)4.9(g)-242.7(c)-2(h)4.9(a)-2(n)4.9(g)-.8(es)-242.5(to)-237(data.)-239.3(A)4.1(s)-242.5(a)-2(n)-237(a)-2(d)4.9(d)-.8(ed)-242.7(secu)4.9(rit)4.8(y)]TJ
T*
.0113 Tc
[(featu)4.4(r)-1.3(e,)-499(the)-497.8(u)-1.3(s)4.6(e)-2.5(r)-496.6(w)-2.2(as)-502.2(au)4.4(to)4.4(mati)4.3(call)4.3(y)-502.4(l)-1.4(o)4.4(g)-1.3(g)4.4(e)-2.5(d)-496.6(o)-1.3(u)4.4(t)-502.5(after)-502.4(1)4.4(0)]TJ
0 -1.1174 TD
.0122 Tc
[(mi)5.2(nut)5.2(es)-409.2(of)-415.1(i)5.2(n)-.4(act)5.2(i)-.5(v)5.3(ity)5.3(,)-411.7(r)-.4(equi)5.2(ri)5.2(ng)-415.1(a)-410.5(p)-.4(ass)5.5(w)-1.3(or)5.4(d)-415.1(t)5.2(o)-415.1(r)-.4(est)5.2(a)-1.6(r)5.4(t)-415.2(th)5.3(e)]TJ
0 -1.1116 TD
.0124 Tc
[(app)5.5(l)-.3(i)5.4(c)-1.4(ati)5.4(on.)-348.1(An)-351.6(ed)5.5(it)-351.7(ch)5.5(eck)-357.3(f)5.6(uncti)5.4(on)-351.6(in)-351.6(th)5.5(e)-352.7(for)5.6(m)-352.8(o)-.2(f)-351.5(a)-358.5(Dat)5.4(a)]TJ
T*
.0122 Tc
[(Clari)5.2()-.3(cat)5.2(i)-.5(on)-443.9(Fo)5.3(rm)-450.9(was)-449.5(d)5.3(ev)5.3(el)5.2(op)5.3(ed)-449.7(t)5.2(o)-449.7(check)-449.7(f)5.4(or)-449.6()5.5(a)-1.6(g)5.3(g)-.4(i)5.2(ng,)]TJ
T*
[(mi)5.1(ssi)5.1(ng)5.2(,)-359.9(i)-.6(n)5.2(v)-.5(ali)5.1(d)-.5(,)-359.9(i)5.1(ncompl)5.1(et)5.1(e,)-360(o)5.2(r)-357.6(qu)5.2(es)5.4(tio)5.2(nabl)5.1(e)-358.8(d)-.5(ata)-358.8(a)4.1(nd)-357.6(re-)]TJ
0 -1.1174 TD
.0119 Tc
[(qui)4.9(red)-300.2(s)-.5(t)4.9(u)-.7(d)5(y-s)5.2(it)4.9(e)-301.4(c)3.9(lar)5.1(i)-.8()5.2(c)-1.9(atio)5(n)-300.2(b)5(ef)5.1(ore)-295.6(th)5(e)-301.4(d)-.7(ata)-295.6(w)-1.6(ere)-301.4(m)3.8(arked)]TJ
0 -1.1116 TD
.0114 Tc
[(as)-329.3(comp)4.5(let)4.4(e)-2.4(.)-331.9(I)4.6(nd)4.5(iv)4.5(idu)4.5(a)-2.4(l)-329.6(s)-1(i)4.4(t)-1.3(es)-335.1(h)4.5(a)-2.4(d)-329.5(a)-2.4(ccess)-329.3(t)-1.3(o)-329.5(o)-1.2(n)4.5(l)-1.4(y)-329.5(t)-1.3(heir)-329.5(own)]TJ
T*
.0072 Tc
[(d)-5.4(a)-6.6(ta)-6.6(.)-445.5(T)-.8(h)-5.4(e)-444.3(pr)-5.4(o)-5.4(j).2(e)-6.6(c)-.8(t)-449(m)-.9(an)-5.4(a)-6.6(g).3(e)-6.6(r)-443.1(a)-6.6(n).3(d)-443.2(s)-5.2(t)-5.5(a)-.8(t)-5.5(i).2(s)-5.2(t)-5.5(ic)-6.6(ia)-6.6(ns)-448.7(we)-6.6(re)-450.1(ab)-5.4(le)-450.1(to)]TJ
0 -1.1174 TD
.0132 Tc
[(acc)5.2(es)6.5(s)-275.7(a)-.6(ll)-276(d)6.3(a)-.6(t)6.2(a)-282.8(f)6.4(r).6(o)6.3(m)-277.1(th)6.3(e)-282.8(s)6.5(it)6.2(es.)]TJ
1.0137 -1.1116 TD
0 Tc
[(During)-318.6(the)-321.4(project,)-319(the)-315.6(data)-317.9(system)-319.8(was)-321.9(evaluated)-320.1(by)-319(the)]TJ
-1.0137 -1.1116 TD
[(participati)-10.5(ng)-244.1(frameworks)-257.1(to)-250(ensure)-250.6(that)-247.7(it)-250.1(was)-252.8(t)-244.1(for)-250.9(purpose)]TJ
0 -1.1174 TD
[(and)-257.9(to)-255.8(access)-258.5(the)-258(training)-252.2(requirements)-259.9(for)-256.7(each)-255.6(site.)-256.7(Central)]TJ
0 -1.1116 TD
[(training)-246.5(for)-245.1(all)-240.9(users)-242.4(was)-247.1(undertaken)-245(by)-238.3(ILF)-246.2(project)-240.7(mana)-8(ger)]TJ
T*
[(and)-286.7(data)-277.6(management)-289(team.)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 323.0361 265.2661 Tm
[(Data)-419.8(transfer)-416.1(and)-417.9(compliance.)]TJ
/F4 1 Tf
9.843 0 0 9.843 454.9038 265.2661 Tm
.0088 Tc
[(The)-356.3(s)-3.6(tudy)-360.9(fa)-5(ce)-5(d)-355.2(i)-3.9(mpor-)]TJ
-14.4108 -1.1116 TD
.0124 Tc
[(tan)5.5(t)-184.7(co)5.5(nsi)5.4(d)-.2(eratio)5.5(ns)-184.3(r)5.6(e)-1.4(lati)5.4(ng)-184.5(t)5.4(o)-184.5(dat)5.4(a)-185.7(pr)5.6(ot)5.4(ect)5.4(io)5.5(n)-184.5(a)-1.4(n)5.5(d)-184.5(trans)5.7(f)-.2(er)-184.5(o)5.5(f)]TJ
T*
.0118 Tc
[(dat)4.8(a)-2(.)-204.7(F)-.6(o)4.9(r)-208.1(cou)4.9(n)-.8(tr)5(ies)-208(w)-1.7(i)4.8(t)-.9(h)4.9(i)-.9(n)-208.2(t)4.8(he)-203.6(Eu)4.9(ro)4.9(pean)-208.2(Uni)4.8(o)-.8(n)-208.2(\()5(EU\),)-204.7(th)4.9(e)-209.3(E)3.7(U)]TJ
0 -1.1174 TD
.0132 Tc
[(Dat)6.2(a)-231(Pr)6.4(ot)6.2(ect)6.2(io)6.3(n)-229.8(D)-.3(i)6.2(r).6(ec)5.2(ti)6.2(ve)-231(g)6.3(u).6(id)6.3(es)-229.6(s)6.5(u).6(c)5.2(h)-229.8(leg)6.3(i).5(s)6.5(l).5(at)6.2(io)6.3(n)-229.8(p).6(l)6.2(a)-.6(c)5.2(e)-.6(s)-229.6(a)-.6(r)6.4(e)]TJ
0 -1.1116 TD
.0124 Tc
[(res)5.7(t)-.3(ri)5.4(ct)5.4(io)5.5(ns)-190.1(o)5.5(n)-190.3(t)5.4(h)-.2(e)-185.7(e)-1.4(x)5.5(p)-.2(o)5.5(r)-.2(ti)5.4(ng)-184.5(of)-184.5(co)5.5(nd)5.5(e)-1.4(n)5.5(t)-.3(i)5.4(a)-1.4(l)-184.7(d)-.2(ata)-185.7(t)-.3(o)-184.5(c)-1.4(ou)5.5(nt)5.4(ries)]TJ
T*
.0118 Tc
[(out)4.8(sid)4.9(e)-330.3(t)4.8(h)-.8(e)-324.5(E)-2(U.)-325.7(Th)4.9(is)-323.2(inclu)4.9(d)-.8(es)-328.9(th)4.9(e)-330.3(U)4.1(ni)4.8(ted)-329.1(S)5.1(tat)4.8(e)-2(s)-323.2(w)-1.7(h)4.9(e)-2(re)-324.5(th)4.9(e)]TJ
T*
.0124 Tc
[(dat)5.4(a)-1.4(b)5.5(a)-1.4(se)-277.8(was)-282.2(l)5.4(ocat)5.4(ed.)-279(W)3.3(ith)5.5(in)-282.4(t)5.4(h)-.2(es)5.7(e)-283.6(r)-.2(estr)5.6(ictio)5.5(ns)-282.2(t)5.4(h)-.2(e)-283.6(t)5.4(ran)5.5(s)0(fer)]TJ
0 -1.1174 TD
.0126 Tc
[(of)-276.5(data)-277.6(was)-282(p)5.7(er)5.8(mi)5.6(tt)5.6(ed)-276.5(pr)5.8(ovi)5.6(de)]TJ
12.3546 0 TD
.0132 Tc
[(d)-275.9(t).5(hr)6.4(ee)-277(cr)6.4(it)6.2(eri)6.2(a)-277(we)5.2(re)-277(me)5.2(t:)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 323.0361 173.4236 Tm
0 Tc
()Tj
/F4 1 Tf
9.843 0 0 9.843 331.9369 172.1196 Tm
[(There)-331.5(was)-333.4(conrmation)-332.5(that)-334.1(the)-332.9(system)-331.3(complied)-335.2(with)]TJ
0 -1.1116 TD
[(all)-454(EU)-447.8(Data)-451.2(Protection)-451.3(legisl)-8(ations)-451.3(and)-448(could)-450.3(ensure)]TJ
T*
[(that)-334.1(sensitive)-340.5(health)-331.7(data)-340.9(were)-335.9(protected.)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 323.0361 140.5417 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 331.9369 139.2377 Tm
[(The)-334(data)-335.2(were)-341.6(anonymized.)]TJ
/F9 1 Tf
7.9702 0 0 7.9702 323.0361 129.5999 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 331.9369 128.296 Tm
[(Patients)-437.4(gave)-432.9(explicit)-437.9(consent)-436.2(to)-434.3(the)-436.6(transfer)-437.2(of)-434.1(their)]TJ
T*
[(data)-335.2(to)-336.4(a)-330.6(country)-337.3(outside)-337.2(the)-332.9(EU.)]TJ
-.9043 -1.7222 TD
[(In)-497.5(sites)-496.1(where)-504(transfer)-500.5(of)-491.7(data)-502.2(outside)-498.5(of)-497.5(Europe)-492.8(was)]TJ
-1.0137 -1.1116 TD
[(prohib)-6.7(ited)-311.1(due)-309.7(to)-307.6(research)-312.7(governance)-315.2(issues,)-316(the)-309.9(data)-312.1(were)]TJ
0 -1.1174 TD
[(entered)-408.7(on)-405.4(to)-405.5(a)-405.4(password-protected)-411(data)-410(collection)-406.7(system)]TJ
0 -1.1116 TD
[(using)-512.3(the)-505.7(same)-514.6(data)-508(capture)-512.4(elds)-507.5(and)-511.3(stored)-508.8(on)-509.1(secure)]TJ
T*
(servers.)Tj
ET
62.022 133.909 239.131 .22678 re
f
62.022 56.58 239.131 .22678 re
f
62.022 105.222 239.131 .28348 re
f
BT
/F8 1 Tf
9.845 0 0 9.845 109.2472 149.5559 Tm
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(8.)Tj
/F8 1 Tf
1.2496 0 TD
[(Interrater)-333.4(Reliability)]TJ
-1.3705 -1.0135 TD
[(Results)-337(from)-334.2(Japan)]TJ
/F11 1 Tf
-7.6761 -2.8562 TD
[(Rater)-335.5(ID)]TJ
7.751 1.0135 TD
[(Agreement)-336.9(rate)]TJ
-1.336 -1.0135 TD
[(with)-333.5()50.8(gold)-333.4(standard)48.9()]TJ
11.7589 1.0135 TD
[(Cohens)-337.2(kappa)]TJ
.9905 -1.0135 TD
(coefcient)Tj
/F4 1 Tf
-19.1644 -1.8946 TD
[(1)-9519.9(0.88)-8586.6(0.51)]TJ
0 -1.0135 TD
[(2)-9519.9(0.90)-8586.6(0.60)]TJ
T*
[(3)-9519.9(0.94)-8586.6(0.81)]TJ
0 -1.0077 TD
[(4)-9519.9(0.88)-8586.6(0.51)]TJ
ET
62.022 709.512 239.584 .22681 re
f
62.022 522.595 239.584 .28351 re
f
62.022 690.803 239.584 .28345 re
f
BT
/F8 1 Tf
9.845 0 0 9.845 96.8315 725.1588 Tm
(Table)Tj
/F4 1 Tf
2.9944 0 TD
(7.)Tj
/F8 1 Tf
1.2554 0 TD
[(Modied)-330.7(Fukazawa)-337.4(Method)]TJ
-6.3056 -1.0135 TD
[(of)-337(Assessment)-334.7(for)-332.2(Detection)-339.1(of)-331.2(Pitting)-336.3(Edema)]TJ
/F11 1 Tf
-1.4799 -1.8427 TD
[(Grade)-11374.1(Criteria)]TJ
/F4 1 Tf
0 -1.8946 TD
[(0)-6243.3(There)-336.7(is)-330.2(no)-336(impression)-334.7(\(no)-337(edema)-332.1(present\))]TJ
0 -1.0135 TD
[(1)-6243.3(Impression)-334.5(of)-336(the)-332.6(outline)-336.9(of)-330.2(the)-338.3(dimple)-331.1(is)]TJ
7.7337 -1.0135 TD
[(slightly)-336.7(differentiated)-336(by)-336(release)-334.1(of)]TJ
0 -1.0077 TD
[(pressure)-338.2(and)-332.4(sometimes)-336.1(appears)]TJ
0 -1.0135 TD
[(to)-336.2(be)-331.4(absent)]TJ
-7.7337 -1.0135 TD
[(2)-6243.3(Impression)-334.5(does)-333.2(not)-337.1(become)-333.1(clear)-336.9(at)-337.3(the)]TJ
7.7337 -1.0135 TD
[(beginning)-332.9(of)-336(pressure)-338.2(but)-331.4(occurs)-336.3(with)]TJ
0 -1.0077 TD
[(further)-336.5(pressure)-338.2(and)-332.4(an)-331.4(impression)]TJ
0 -1.0135 TD
[(is)-336(left)-333.7(after)-335.7(release)]TJ
-7.7337 -1.0135 TD
[(3)-6243.3(Deep)-335.4(impression)-334.7(remains)-338.7(after)-335.7(release)]TJ
7.7337 -1.0135 TD
[(of)-336(pressure)-332.4(that)-339.5(is)-330.2(clear)-336.9(on)-336(visual)]TJ
0 -1.0077 TD
[(inspection)-335.1(at)-337.3(initiation)-334.6(of)-336(pressure)]TJ
-7.7337 -1.0135 TD
(Nonpitting)Tj
.9905 -1.0135 TD
(Edema)Tj
T*
(\(added)Tj
0 -1.0077 TD
[(to)-336.2(method\))]TJ
5.7528 3.0348 TD
[(Indentation)-336.2(made)-335.7(by)-330.2(pressure)-338.2(does)]TJ
.9905 -1.0135 TD
[(not)-337.1(persist)-330.6(\(nonpitting)-334.1(edema)-337.9(as)-337(seen)]TJ
T*
[(in)-336.2(patients)-333.1(with)-333.4(hard)-339.1(tissue\))]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(132)Tj
46.3153 0 TD
[(MOFFATT)-333.6(ET)-338.7(AL.)]TJ
ET
endstream
endobj
60 0 obj
<>stream
/GS1 gs
BT
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 725.7825 Tm
0 0 0 rg
0 Tc
0 Tw
[(Phase)-333.1(1.)-336.7(Stage)-330.8(7.)-336.7(Development)-334.5(of)-330.4(an)-337.6(international)]TJ
0 -1.2203 TD
[(protocol)-336(and)-335.7(sampling)-335.2(frameworks)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 698.3998 Tm
[(The)-293.6(international)-294.9(protocol)-286.7(included)-293.6(a)-290.2(detailed)-294.9(description)]TJ
-1.0137 -1.1174 TD
[(of)-261.4(the)-258(sampling)-258.9(procedures)-261.9(and)-257.9(study)-253.1(methods)-263.5(and)-257.9(was)-258.6(used)]TJ
0 -1.1116 TD
[(in)-284.6(all)-281.2(sites.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 654.3494 Tm
[(Methods)-338.5(for)-332.5(sampling)-335.2(in)-330.2(geographically)-337.3(based)]TJ
0 -1.2203 TD
[(prevalence)-334.5(study)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 626.9668 Tm
[(A)-330.3(comprehens)-9.8(ive)-327.1(list)-332.9(was)-333.4(collated)-335.2(for)-331.5(each)-336.2(geographical)]TJ
-1.0137 -1.1116 TD
[(area)-428.3(of)-416.9(all)-425.2(acute)-423.8(hospitals)-420(and)-419.2(relevant)-427.2(community)-422.7(health)]TJ
0 -1.1174 TD
[(services)-467(that)-460.8(may)-466.5(meet)-463.1(people)-458.3(who)-465(have)-461.7(chronic)-465.1(edema.)]TJ
0 -1.1116 TD
[(Examples)-284.2(of)-284.4(such)-281.8(services)-282.7(included:)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 69.4488 577.6439 Tm
(B)Tj
/F4 1 Tf
9.843 0 0 9.843 78.6897 577.6439 Tm
[(General)-340.5(medical)-335.2(practitioner.)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 69.4488 566.7022 Tm
(B)Tj
/F4 1 Tf
9.843 0 0 9.843 78.6897 566.7022 Tm
[(Specialist)-337.2(community)-336.3(medical)-341(practitioner.)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 69.4488 555.7605 Tm
(B)Tj
/F4 1 Tf
9.843 0 0 9.843 78.6897 555.7605 Tm
[(Community)-336.2(nursing/home)-338.2(care)-336.2(nursing)-335.9(service.)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 69.4488 544.7621 Tm
(B)Tj
/F4 1 Tf
9.843 0 0 9.843 78.6897 544.7621 Tm
[(Nursing)-336.8(home.)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 69.4488 533.8203 Tm
(B)Tj
/F4 1 Tf
9.843 0 0 9.843 78.6897 533.8203 Tm
[(Elderly)-338.6(care)-336.2(residential)-338.4(home.)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 69.4488 522.8786 Tm
(B)Tj
/F4 1 Tf
9.843 0 0 9.843 78.6897 522.8786 Tm
[(Specialist)-337.2(lymphedem)-9.1(a)-330.6(service.)]TJ
/F10 1 Tf
3.9849 0 0 3.9849 69.4488 511.8802 Tm
(B)Tj
/F4 1 Tf
9.843 0 0 9.843 78.6897 511.8802 Tm
[(Acute)-337.1(hospital)-338.5(services)-334.6(\(in-patient)-337.4(or/and)-336.2(outpatient\).)]TJ
-.91 -1.1116 TD
.0091 Tc
[(A)-373(s)-3.3(am)-4.7(pling)-372.1(f)-3.5(ra)-4.7(me)-373.3(w)-4.4(a)1.1(s)-371.9(c)-4.7(re)-4.7(ated,)-374.5(w)1.4(ith)-372.1(t)-3.6(he)-373.3(a)-4.7(i)2.1(m)-373.4(o)-3.5(f)-372.1(t)2.1(he)-373.3(re-)]TJ
-1.0137 -1.1116 TD
.0072 Tc
[(c)-6.6(r)-5.4(ui)-5.5(tm)-6.6(en)-5.4(t)-201.4(s)-5.2(tr)-5.4(at)-5.5(eg)-5.4(y)-201.2(t)-5.5(o)-201.2(e)-6.6(ns)-5.2(ur)-5.4(e)-202.4(t)-5.5(ha)-6.6(t)-201.4(t)-5.5(he)-208.2(wi)-5.5(de)-6.6(st)-207.1(ra)-6.6(ng)-5.4(e)-202.4(o)-5.4(f)-201.2(p)-5.4(at)-5.5(ie)-6.6(nt)-5.5(s)]TJ
0 -1.1174 TD
.012 Tc
[(were)-474.1(id)5.1(ent)5(i)-.7()5.3(e)-1.8(d)-472.9(w)-1.5(i)5(t)-.7(h)-472.9(d)-.6(i)5(fferent)-473(un)5.1(derl)5(yin)5.1(g)-478.7(con)5.1(d)-.6(i)5(t)-.7(i)5(ons)-472.7(an)5.1(d)]TJ
0 -1.1116 TD
.0131 Tc
[(co)6.2(mo)6.2(rbi)6.1(di)6.1(ti)6.1(es.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 445.9463 Tm
0 Tc
[(Hospital)-335.5(prevalence)-334.5(studies)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 429.5054 Tm
[(In)-198(hospital)-194.5(settings,)-197.7(a)-198.1(sampling)-195.6(framework)-204.3(of)-192.2(all)-194.8(wards)-203.1(and)]TJ
-1.0137 -1.1116 TD
[(departments)-276.1(in)-273(which)-272.6(patients)-276.3(with)-270.5(chronic)-269.3(edem)-8(a)-267.2(would)-271.5(be)]TJ
T*
[(found)-425.9(was)-425.6(developed.)-425.9(The)-426.1(screening)-428(was)-419.8(undertaken)-429.3(in)-422.8(a)]TJ
T*
[(single)-359.2(day)-355.8(or)-353.5(over)-356.9(several)-356.7(days)-356.7(in)-353.7(larger)-354.6(facilities.)-358.2(Trained)]TJ
0 -1.1174 TD
[(staff)-300.3(screened)-301.2(all)-298.5(patients)-299.3(who)-297.9(consented)-301.3(to)-296.1(participate)-305.2(irre-)]TJ
0 -1.1116 TD
[(spective)-421.3(of)-416.9(their)-415.8(underlying)-415.6(disease)-419.9(or)-416.9(treatment)-418.2(regimen.)]TJ
T*
[(Teams)-303.8(of)-301.7(researchers)-311.2(undertook)-299.2(the)-304.1(study)-299.2(with)-305(a)-301.8(lympholo-)]TJ
0 -1.1174 TD
[(gist)-361.6(assigned)-356.5(to)-359.4(each)-359.2(team)-359.4(to)-353.7(undertake)-359.1(the)-355.9(chronic)-361.5(edema)]TJ
0 -1.1116 TD
(classication.)Tj
1.0137 -1.1116 TD
[(The)-287.9(bed)-286.7(capacity)-290.2(of)-290.2(each)-284.4(ward)-288.6(or)-290.2(unit)-286.9(was)-287.4(recorded,)-286.4(plus)]TJ
-1.0137 -1.1174 TD
[(the)-459.6(number)-452.5(of)-457.2(beds)-454.6(occupied,)-459.4(the)-453.8(number)-458.2(of)-457.2(patients)-454.8(re-)]TJ
0 -1.1116 TD
[(cruited,)-238.3(and)-229.1(the)-235(number)-233.6(excluded)-237.1(from)-230.2(consideration)-236.8(and)-229.1(the)]TJ
T*
[(reasons)-240(for)-239.4(this.)-238.3(This)-235.9(enabled)-236(the)-240.7(prevalence)-241.6(to)-232.7(be)-239.5(calculated)]TJ
0 -1.1174 TD
[(accurately)-287.8(in)-278.8(hospital)-286.6(settings.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 264.9826 Tm
[(Community-based)-335.8(prevalence)-334.5(studies)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 248.5417 Tm
[(All)-217.5(staff)-213.9(in)-209.7(relevant)-219.9(community)-215.4(health)-216.5(services)-219.4(were)-214.9(asked)]TJ
-1.0137 -1.1174 TD
[(to)-250(approach)-254.2(each)-255.6(person)-249.5(on)-249.9(their)-254.6(existing)-252.1(case)-249.6(list)-252.3(to)-250(provide)]TJ
0 -1.1116 TD
[(information)-481.4(and)-476.8(gain)-478(consent.)-474.2(All)-476.7(generalist)-481.2(practitioners)]TJ
T*
[(participating)-254.6(in)-244.2(the)-246.5(study)-247.3(received)-249.7(training)-246.5(in)-250(the)-246.5(completion)]TJ
T*
[(of)-301.7(the)-298.3(tools.)-297(The)-299.4(collection)-303(of)-295.9(data)-300.6(took)-298.3(place)-297.1(prospectively)]TJ
0 -1.1174 TD
[(over)-431.8(a)-434.2(time)-427.5(frame,)-438.6(generally)-434.1(of)-428.4(4)-427.3(weeks)-434.7(and)-430.7(required)-431.7(all)]TJ
0 -1.1116 TD
[(patients)-310.8(to)-301.8(be)-302.9(clinically)-308.9(screened)-307(and)-304(assessed.)-308.7(Numbers)-304.5(on)]TJ
T*
[(community)-186.6(caseloads)-187.1(were)-186.1(recorded)-190.8(and)-183(those)-185.2(excluded)-185.2(from)]TJ
0 -1.1174 TD
[(the)-442.3(study.)-446.6(The)-437.6(method)-446.9(of)-439.9(classication)-445.2(of)-445.7(chronic)-442.1(edema)]TJ
0 -1.1116 TD
[(varied)-291.3(in)-290.3(different)-294.6(settings)-292.2(but)-291.4(included)-287.9(the)-292.6(use)-292.3(of)-290.1(specialist)]TJ
T*
[(lymphedema)-483.6(therapist)-473.2(and)-476.8(tissue)-479.9(viability)-472.5(teams)-481.3(in)-474.6(some)]TJ
0 -1.1174 TD
[(settings.)-393.5(In)-388.1(areas)-388.9(where)-394.6(this)-384.6(support)-387.8(was)-391(not)-389.3(available)-389.3(the)]TJ
0 -1.1116 TD
[(more)-260.2(detailed)-254.6(classicatio)-12.1(n)-254.5(was)-252.8(omitted)-258.2(\(three)-256.7(studies)-262.2(in)-250(the)]TJ
T*
[(United)-285.4(Kingdom\).)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 83.9622 Tm
[(Random)-338.3(sampling)-335.2(techniques)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 67.5212 Tm
[(A)-232.4(random)-227.8(sample)-234.7(was)-229.8(used)-230(in)-227(some)-231.2(population)-231.4(or)-226.8(facility-)]TJ
-1.0137 -1.1116 TD
[(based)-255.3(studies,)-254.1(where)-256.3(a)-249.9(large)-255.6(number)-250.9(of)-249.8(patients)-253.2(with)-253.2(chronic)]TJ
25.5097 67.9242 TD
[(edema)-332.8(was)-339.2(identied)-335(but)-331.7(additional)-336.4(modular)-338.5(tools)-333.9(were)-335.9(re-)]TJ
0 -1.1174 TD
[(quired.)-316.6(A)-313(random)-314.2(permuted)-317.7(block)-312.1(design)-318.7(allowed)-316.4(for)-314.3(a)-313.3(one)]TJ
0 -1.1116 TD
[(third)-328.3(sample)-332.6(to)-330.6(be)-331.7(taken.)-333.9(Following)-327.8(completion)-331.7(of)-330.5(the)-332.9(core)]TJ
T*
[(tool,)-353.7(the)-361.7(investigator)-361.4(checked)-357.9(the)-355.9(patient)-361.8(numbers)-355.5(of)-359.3(those)]TJ
T*
[(identied)-427.2(with)-431.8(chronic)-424.8(edema)-430.7(against)-430.6(a)-428.5(pregenerated)-433.8(ran-)]TJ
0 -1.1174 TD
[(domized)-236(list)-235(of)-232.6(sequential)-239.3(patient)-240.8(numbers)-234.5(to)-232.7(decide)-240.6(whether)]TJ
0 -1.1116 TD
[(the)-240.7(patient)-246.6(was)-247.1(to)-244.2(be)-245.3(interviewed.)-250.7(Each)-244.1(clinical)-249(team)-244.2(held)-247.6(an)]TJ
T*
[(individual)-283.4(randomization)-284.4(list.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 310.8472 625.3794 Tm
[(Specialist)-333.5(service)-335.3(proles)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 608.9384 Tm
[(LIMPRINT)-330.6(provided)-326.9(a)-330.6(unique)-324.7(opportunity)-329.3(to)-330.6(understand)]TJ
-1.0137 -1.1116 TD
[(the)-223.5(prole)-220.8(of)-221(patients)-224.4(seen)-225.4(within)-221(specialist)-227.7(lymphedema)-224.5(and)]TJ
T*
[(other)-271.7(types)-271.6(of)-272.9(services)-277(in)-273(different)-277.4(countries)-271.5(and)-275.2(to)-273(compare)]TJ
T*
[(this)-361.6(with)-362.6(patients)-368.4(found)-362.6(in)-359.4(other)-363.9(settings.)-364.8(Patients)-368.3(gave)-363.8(in-)]TJ
0 -1.1174 TD
[(formed)-210.5(consent)-211.6(for)-204.8(their)-214.2(inclusion)-207.1(in)-209.7(study)-207(sites,)-211.6(where)-210.3(ethics)]TJ
0 -1.1116 TD
[(approval)-282(required)-287.7(this.)-278.6(The)-282.1(accuracy)-285.3(of)-284.4(the)-281.1(service)-287.6(lists)-282(was)]TJ
T*
[(checked)-346.4(to)-342.1(ensure)-348.5(that)-345.6(it)-342.3(was)-345(up)-347.8(to)-342.1(date)-346.7(and)-344.3(discharge)-347.4(and)]TJ
0 -1.1174 TD
[(deaths)-262.3(had)-257.9(been)-265.9(removed.)-262.3(Information)-262.3(on)-261.4(their)-260.3(edema)-263.6(status)]TJ
0 -1.1116 TD
[(was)-229.8(based)-232.3(on)-226.8(their)-231.5(last)-224.5(visit)-230.3(and)-229.1(the)-229.2(type)-230.3(of)-226.8(lymphedema)-236(was)]TJ
T*
[(taken)-203.8(from)-201.4(the)-206.2(clinical)-202.9(case)-203.5(records.)-209(As)-204.5(these)-203.6(patients)-201.4(were)-209.2(in)]TJ
0 -1.1174 TD
[(specialist)-262.3(lymphedema)-259(services,)-263.1(the)-258(underlying)-260.1(stratication)]TJ
0 -1.1116 TD
[(of)-388.1(primary)-390.3(and)-390.4(secondary)-393.3(lymphedema)-397.2(was)-391(already)-391.4(deter-)]TJ
T*
[(mined)-296(in)-296.1(addition)-298.3(to)-296.1(the)-298.3(comorbidities)-306.2(required)-299.2(for)-297(comple-)]TJ
T*
[(tion)-281.1(of)-278.6(the)-281.1(core)-283.2(tool.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 310.8472 443.4518 Tm
[(Phase)-333.1(1.)-330.4(Stage)-337.2(8.)-330.4(Development)-334.5(of)-336.7(a)-333.2(support)-332.7(manual)]TJ
0 -1.2203 TD
[(and)-329.4(educational)-337.8(tools)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 416.0692 Tm
[(LIMPRINT)-336.3(required)-339.5(the)-332.9(development)-339.7(of)-330.5(a)-336.3(range)-336.1(of)-336.2(edu-)]TJ
-1.0137 -1.1116 TD
[(cational)-312.2(materials)-314.3(to)-313.4(ensure)-308.2(that)-311.1(the)-315.6(data)-312.1(were)-312.8(collected)-314.5(ac-)]TJ
0 -1.1174 TD
[(curately.)-240.6(This)-247.4(included)-241.8(a)-238.4(manual)-246.4(to)-238.5(supplement)-245(the)-240.7(protocol.)]TJ
0 -1.1116 TD
[(Formal)-613.7(training)-609.3(standards)-616.7(were)-618.1(written)-609.1(that)-616.4(included)-610.4(a)]TJ
T*
[(checklist)-278.5(of)-272.9(training)-275.3(and)-275.2(competenc)-10.2(y)-271.8(for)-273.9(all)-275.4(those)-277.3(collecting)]TJ
T*
[(data.)-200.4(A)-203.6(video)-202.6(using)-201.3(reuseable)-204.5(learning)-207.2(outcomes)-202.4(was)-206.7(made)-203.8(to)]TJ
0 -1.1174 TD
[(demonstrate)-258.8(how)-251.8(to)-250(undertake)-255.4(the)-258(pitting)-250.1(test,)-256.7(recognition)-256.7(of)]TJ
0 -1.1116 TD
[(a)-555.2(positive)-563.1(stemmer)-559.6(sign,)-560.7(and)-557.4(brosis.)-557.9(All)-563.1(facility-based)]TJ
T*
[(studies)-423.4(commenced)-426(with)-426(a)-422.7(half)-426.1(day)-424.9(training)-425(program)-424.7(that)]TJ
0 -1.1174 TD
[(included)-293.6(checking)-294.7(of)-295.9(the)-292.6(rst)-292.1(assessment)-303.1(by)-290.2(specialist)-296.9(prac-)]TJ
0 -1.1116 TD
[(titioners.)-256.7(Data)-255.4(quality)-256.9(was)-252.8(enhanced)-261.1(by)-249.9(teams)-256.7(of)-255.6(researchers)]TJ
T*
[(working)-302.4(in)-301.8(clinical)-300.8(areas,)-306(where)-302.4(any)-304(complex)-299.4(clinical)-306.6(ques-)]TJ
0 -1.1174 TD
[(tions)-282(could)-277.5(be)-285.6(conrmed)-282.9(before)-279.6(leaving)-286.8(the)-281.1(area.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 310.8472 261.5244 Tm
[(Phase)-333.1(1.)-330.4(Stage)-337.2(9.)-330.4(Establishment)-337.8(of)-330.4(quality)]TJ
0 -1.2203 TD
[(control)-331.5(mechanisms)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 234.1417 Tm
[(A)-278.4(range)-284.3(of)-278.6(quality)-280(control)-285.6(mechanisms)-281.7(was)-281.6(established.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 310.8472 211.1244 Tm
[(Preventing)-332(double)-335.2(counting)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 194.6834 Tm
[(The)-184.2(prevention)-192.1(of)-180.7(double)-192.2(counting)-183(was)-189.5(essential)-192(to)-186.6(achieve)]TJ
-1.0137 -1.1174 TD
[(an)-256.8(accurate)-268.1(prevalence.)-262.3(The)-259.1(double)-261.3(counting)-263.7(of)-255.6(patients)-264.8(was)]TJ
0 -1.1116 TD
[(likely)-221.3(to)-215.4(take)-220(place)-222.2(within)-221(a)-221.1(geographical)-225.5(area)-221(when)-219.6(a)-221.1(patient)]TJ
T*
[(might)-266.2(be)-262.5(identied)-265.9(by)-261.4(more)-265.9(than)-264.9(one)-269.4(service)-264.5(delivering)-267.1(care)]TJ
0 -1.1174 TD
[(to)-382.5(the)-390.5(same)-387.9(patient)-390.6(or)-388.1(in)-382.5(an)-389.3(acute)-389.3(care)-388(setting)-389.2(if)-388.2(a)-388.2(patient)]TJ
0 -1.1116 TD
[(moved)-180.7(departments.)-187.3(This)-184.1(was)-183.7(prevented)-186.3(by)-180.7(the)-183.1(allocation)-182.1(of)-186.5(a)]TJ
T*
[(nonidentiable)-549.2(number)-550.4(that)-547.2(was)-552.3(matched)-548.2(with)-552.7(a)-543.7(master)]TJ
T*
[(identier)-283.1(list)-281.1(of)-278.6(patients.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 310.8472 94.9039 Tm
[(Data)-331.3(quality)-339.1(checks)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 78.463 Tm
[(In)-238.3(addition)-246.5(to)-244.2(the)-240.7(quality)-245.4(checks)-246.1(within)-244(the)-246.5(electronic)-246.4(data)]TJ
-1.0137 -1.1116 TD
[(system,)-225.3(additional)-227(checks)-228.8(were)-232.2(made)-226.8(of)-221(the)-229.2(paper-based)-229.6(data)]TJ
T*
[(collection)-303(tools.)-297(Within)-297.2(each)-301.6(facility,)-297.3(quality)-303(monitors)-298.1(were)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(LIMPRINTMETHODS)-344.1(AND)-330.9(VALIDATION)]TJ
53.0113 0 TD
(133)Tj
ET
endstream
endobj
64 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(established)-257.5(to)-255.8(check)-256.7(completeness)-260.9(of)-249.8(data)-260.3(from)-253.2(each)-255.6(clinical)]TJ
0 -1.1174 TD
[(area)-197.9(before)-198.9(the)-194.7(research)-203.3(teams)-193.3(left)-201.6(the)-194.7(area)-197.9(and)-194.5(all)-194.8(forms)-196.5(were)]TJ
0 -1.1116 TD
[(checked)-300.4(by)-295.9(a)-296(central)-299.4(coordinator.)-300.3(Similar)-298.3(mechanisms)-298.9(were)]TJ
T*
[(established)-286.3(for)-279.7(community)-284.5(studies.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 670.3369 Tm
(Conclusion)Tj
/F4 1 Tf
9.843 0 0 9.843 72 653.8959 Tm
[(The)-397.3(standardization)-407.4(of)-399.6(methods)-395.9(used)-402.8(in)-399.7(the)-396.2(LIMPRINT)]TJ
-1.0137 -1.1116 TD
[(study)-379.8(provided)-372.9(a)-382.4(framework)-377.1(that)-380.2(allowed)-379.8(sites)-375.2(in)-376.7(different)]TJ
T*
[(countries)-202.3(and)-194.5(from)-195.6(different)-196.7(facilities)-205(and)-194.5(types)-196.7(of)-198(health)-193.5(care)]TJ
0 -1.1174 TD
[(systems)-188.2(to)-192.4(work)-183.8(together.)-193.4(The)-190(completion)-187.8(of)-186.5(LIMPRINT)-192.3(also)]TJ
0 -1.1116 TD
[(demonstrated)-588.2(that)-587.6(an)-585.1(international)-588.6(initiative,)-593.5(which)-583.6(was)]TJ
T*
[(supported)-322(by)-324.7(a)-319(strong)-323.3(ethos)-323.4(of)-324.7(partnership,)-323.1(could)-323.6(be)-325.9(under-)]TJ
0 -1.1174 TD
[(taken.)-218.7(The)-213(results)-216.1(from)-218.7(the)-211.9(different)-219.8(studies)-216.1(will)-213(be)-216.5(discussed)]TJ
0 -1.1116 TD
[(in)-278.8(a)-284.5(portfolio)-280.9(of)-278.6(articles.)]TJ
1.0137 -1.1116 TD
[(The)-282.1(LIMPRINT)-290.3(team)-284.5(would)-283(like)-288(to)-278.8(thank)-283.3(all)-286.9(the)-286.8(sites)-283(for)]TJ
-1.0137 -1.1116 TD
[(their)-375.5(contribution)-383.5(in)-376.7(generating)-377.6(the)-379(data)-375.5(for)-377.6(this)-378.8(study)-374.1(and)]TJ
0 -1.1174 TD
[(their)-283.4(commitment)-282.4(to)-278.8(the)-286.8(ILF.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 522.425 Tm
[(Author)-338.7(Disclosure)-330.4(Statement)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 505.9841 Tm
[(No)-279.5(competing)-284.4(nancial)-283.1(interests)-282.9(exist.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 484.0439 Tm
(References)Tj
/F4 1 Tf
9.2951 0 0 9.2951 66.6708 467.9999 Tm
[(1.)-500.4(International)-889(Lymphoedema)-893.5(Framework.)]TJ
/F11 1 Tf
19.9323 0 TD
(International)Tj
-18.682 -1.1284 TD
[(Consensus:)-540.7(Best)-541.9(Practice)-544.3(for)-541.8(the)-540.8(Management)-544(of)-536.4(Lym-)]TJ
0 -1.1223 TD
(phoedema)Tj
/F4 1 Tf
4.117 0 TD
[(.)-292.8(London:)-301.2(Medical)-298.4(Education)-303.2(Partnership)-296.1(\()-87.8(MEP\))]TJ
-4.117 -1.1284 TD
[(Ltd.;)-336.8(2006.)]TJ
-1.2503 -1.1223 TD
[(2.)-500.4(Hiltz)-340.2(SR,)-343.5(Coppola)-344.9(N,)-337.3(Rotter)-346.5(N,)-337.3(Turoff)-345.2(M,)-341(Benbunan-Fich)]TJ
1.2503 -1.1284 TD
[(R.)-352.7(Measuring)-363.6(the)-351.7(importance)-362.5(of)-356.4(collaborative)-354.2(learning)-358.4(for)]TJ
0 -1.1223 TD
[(the)-351.7(effectiveness)-354(of)-350.3(ALN:)-352.7(A)-349.4(multi-measure,)-357.3(multi-method)]TJ
0 -1.1284 TD
[(approach.)-601.7(Journal)-597.7(of)-594.2(Asynchronous)-599.7(Learning)-604.8(Networks)]TJ
0 -1.1223 TD
[(2000;)-335.6(4:103125.)]TJ
-1.2503 -1.1284 TD
[(3.)-500.4(Moffatt)-337.3(CJ,)-339.7(Franks)-332.7(PJ,)-337.8(Doherty)-337.9(DC,)-336.1(Williams)-341.6(AF,)-334.2(Badger)]TJ
1.2503 -1.1223 TD
[(C,)-297.8(Jeffs)-300.6(E,)-301(Bosanquet)-305.8(N,)-294.6(Mortimer)-306.6(PS.)-298.9(Lymphoedema:)-301.5(An)]TJ
0 -1.1284 TD
[(underestimated)-341.4(health)-331.4(problem.)-336(QJM)-335.8(2003;)-335.6(96:731738.)]TJ
-1.2503 -1.1223 TD
[(4.)-500.4(Moffatt)-422.7(CJ,)-419(Keeley)-423.1(V,)-416.5(Franks)-418.1(PJ,)-423.2(Rich)-417.6(A,)-422.6(Pinnington)-417.4(L.)]TJ
1.2503 -1.1284 TD
[(Chronic)-353.3(oedema:)-354.2(A)-349.4(prevalent)-350.6(health)-349.7(care)-357.1(problem)-348.1(for)-352.7(UK)]TJ
0 -1.1223 TD
[(health)-288.7(services.)-288.3(Int)-282.7(Wound)-285.6(J)-285.9(2017;)-286.8(14:772781.)-281.5(Version)-288.2(of)]TJ
0 -1.1284 TD
[(Record)-333.5(online:)-339(2016.)]TJ
-1.2503 -1.1284 TD
[(5.)-500.4(INVOLVE.)-568.5(2018.)-561.8(Available)-568.8(at:)-564.6(www.invo.org.uk/about-)]TJ
1.2503 -1.1223 TD
[(involve)-333.4(\(Accessed)-337.4(December)-338.6(15,)-335.8(2018\).)]TJ
-1.2503 -1.1284 TD
[(6.)-500.4(Declaration)-295.1(of)-283.2(Helsinki.)-291.1(World)-287.4(Medical)-292.3(Association.)-294.8(2008.)]TJ
1.2503 -1.1223 TD
[(Available)-599.3(at:)-601.2(www.wma.net/wp-content/uploads/2018/07/)]TJ
0 -1.1284 TD
[(DoH-Oct2008.pdf)-338.4(\(Accessed)-337.4(Decemeber)-336.9(15,)-335.8(2018\).)]TJ
-1.2503 -1.1223 TD
[(7.)-500.4(Dai)-261.8(M,)-255.6(Sugama)-261.8(J,)-261.6(Tsuchiya)-260.1(S,)-259.3(Sato)-263.3(A,)-258(Matsumato)-262.7(M,)-255.6(Iuchi)]TJ
1.2503 -1.1284 TD
[(T,)-386.4(Maeba)-390.8(H,)-386(Okuwa)-386.2(M,)-389.8(Sanada)-388.4(H,)-386(Moffatt)-386.1(C.)-389.2(Inter-rater)]TJ
0 -1.1223 TD
[(reliability)-289.4(study)-279.8(of)-283.2(pitting)-285.4(test)-283.3(for)-285.6(oedema)-287.5(evaluation)-286.8(in)-280.3(the)]TJ
0 -1.1284 TD
[(Kanazawa)-623.1(LIMPRINT)-615.8(study.)-621.5(Lymphoedema)-619.1(Res)-612.4(Pract)]TJ
0 -1.1223 TD
[(2015;)-335.6(3:17.)]TJ
-1.2503 -1.1284 TD
-.0161 Tc
[(8.)-504.1(Stou)-16.1(t)-442.8(N).5(L,)-449.2(Weiss)-454.5(R)-2.7(,)-449.2(F)-.8(eld)-16.1(m)14.5(an)-455.4(JL,)-455.3(S)-.8(tewart)-454.8(B)3.4(R)-2.7(,)-455.3(A).5(rmer)-457.7(JM,)]TJ
1.2198 -1.1223 TD
-.0153 Tc
[(C)4.2(o)-15.3(r)12.6(m)3.3(ie)4.8(r)-243.4(J)-2.4(N,)-241(Sh)-15.3(i)15.5(h)-241.1(Y)-15.3(-)11(C)4.2(T)1(.)-247.1(A)-242.7(sy)-15.3(s)15.8(t)-2.7(e)4.8(m)-2.8(atic)-239.2(review)-242.7(of)-243.4(care)-239.2(d)-15.3(e)10.7(l)3.4(ivery)]TJ
0 -1.1284 TD
-.0157 Tc
[(mo)-15.7(d)14.5(e)-1.7(ls)-246.7(and)-241.5(econ)-15.7(o)14.5(mic)-245.7(a)-1.7(nalyses)-240.6(i)-3.1(n)-241.5(l)-3.1(ymphedema)4.4(:)-247(H).9(ealth)-241.5(p)-15.7(o)14.5(licy)]TJ
0 -1.1223 TD
-.0175 Tc
[(im)-5(pact)-334.2(\(200)-17.5(4)12.7().7(2)-17.5(0)12.7(11)-17.5(\))10.4(.)-334.7(Lym)-5(pho)-17.5(l)13.3(o)-17.5(g)12.7(y)-334.8(20)-17.5(1)12.7(3).7(;)-334.2(4)-17.5(6)12.7(:)-4.9(27)-17.5(4)12.7(1).7(.)]TJ
25.7876 60.3031 TD
0 Tc
[(9.)-500.4(Moffatt)-349.5(CJ,)-345.8(Franks)-344.9(PJ,)-343.9(Doherty)-350.1(DC,)-342.2(Martin)-347.1(R,)-346.6(Blewett)-349.5(R,)]TJ
1.2503 -1.1223 TD
[(Ross)-412.2(F.)-411.8(Prevalence)-411.4(of)-411.3(Leg)-409.1(ulceration)-411.1(in)-414.5(a)-406.9(London)-411.4(Popu-)]TJ
0 -1.1284 TD
[(lation.)-338.9(QJM)-335.8(2004;)-329.5(97:431437.)]TJ
-1.7505 -1.1223 TD
[(10.)-500.5(WHO)-337.3(obesity)-338.6(Branca)-337.7(F,)-332.5(Nikogosian)-334.6(H,)-337.3(Lobstein)-334.6(T.)-337.6(\(Eds.\))]TJ
/F11 1 Tf
1.7505 -1.1283 TD
[(The)-434.5(Challenge)-428.1(of)-432.8(Obesity)-429.8(in)-432.8(the)-431(WHO)-426.9(European)-433.3(Region)]TJ
0 -1.1223 TD
[(and)-445.7(the)-449.3(Strategies)-445.5(for)-444.2(Response)]TJ
/F4 1 Tf
13.4671 0 TD
[(.)-445.3(Denmark:)-445.5(WHO;)-446.7(2007.)]TJ
-13.4671 -1.1284 TD
[(Available)-745.7(at:)-735.4(http://books.google.co.uk/books?hl=en&lr=)]TJ
0 -1.1223 TD
.0074 Tc
[(&)-4.5(i)7.4(d)-10.6(=)7.4(Q)-5.6(R)-3.6(LSk7M)-4.2(_6n)-4.9(AC&)7.4(o)-4.7(i)-4.4(=)7.4(f)-6.4(n)-4.9(d&)7.4(p)-10.8(g)1.2(=)7.4(P)-7(A1)-4.9(&)7.4(d)-4.7(q)-4.9(=)7.4(c)-8.3(h)1.2(ang)-4.9(i)7.4(n)-4.5(g)]TJ
/F5 1 Tf
23.3845 0 TD
0 Tc
(+)Tj
/F4 1 Tf
-23.3845 -1.1284 TD
-.021 Tc
[(prevalenc)5.1(e)]TJ
/F5 1 Tf
4.1353 0 TD
0 Tc
(+)Tj
/F4 1 Tf
.5306 0 TD
-.0243 Tc
(of)Tj
/F5 1 Tf
.7929 0 TD
0 Tc
(+)Tj
/F4 1 Tf
.5245 0 TD
-.0189 Tc
[(ob)5.4(esi)5.9(t)-.2(y)]TJ
/F5 1 Tf
2.7447 0 TD
0 Tc
(+)Tj
/F4 1 Tf
.5306 0 TD
-.0248 Tc
(in)Tj
/F5 1 Tf
.738 0 TD
0 Tc
(+)Tj
/F4 1 Tf
.5306 0 TD
-.0247 Tc
[(eu)-6.5(rop)-6.5(e)]TJ
/F5 1 Tf
2.5922 0 TD
0 Tc
(+)Tj
/F4 1 Tf
.5306 0 TD
-.0182 Tc
[(WH)4.5(O&)6.5(o)6.1(t).5(s=)7.1(by)6.1(E)4.2(g)6.1(Ol)6.6(jm)6.5(r)3.7(x)0(&)]TJ
-13.6501 -1.1223 TD
0 Tc
[(si)13.4(g=)12.9(qEK)20.5(lK1)16.9(Oy)16.4(cW8)15.4(Z7)16.1(aJ)14.7(OKw)19.2(8A3)16.3(H7)16.4(37P)21.1(Y#v)22.4(=o)12.9(ne)13.8(pa)13.8(ge&)20.2(q=)]TJ
0 -1.1284 TD
-.0242 Tc
[(ch)6.2(angin)6.2(g).1(%2)6.2(0prevalence%2)6.2(0of)]TJ
11.8569 0 TD
-.0245 Tc
[(%20ob)5.9(es)6.7(ity%20i)6.4(n%2)5.9(0)-.2(europe%)]TJ
-11.8569 -1.1223 TD
-.0251 Tc
[(20WHO&f=false)-328.3(\(Accessed)-330.2(D)-2.4(ecember)-332.5(15,)-330.1(20)5.3(18\).)]TJ
-1.7505 -1.1284 TD
0 Tc
[(11.)-500.5(Ustun)-598.6(TB,)-592.6(Kostanjsck)-594.1(N,)-593.4(Chatterjis)-593.2(S,)-594.7(Rehm)-594.7(J)-590.9(\(Eds\).)]TJ
/F11 1 Tf
1.7505 -1.1284 TD
[(Manual)-393.1(for)-395.4(WHO)-390.3(Disability)-393.8(Assessment)-399.6(Schedule)-391.4(\(WHO-)]TJ
0 -1.1223 TD
[(DAS)-339.4(2.0\))]TJ
/F4 1 Tf
3.751 0 TD
[(.)-335.5(Geneva:)-337.9(World)-330.1(Health)-339.1(Organisation;)-334.3(2010.)]TJ
-5.5015 -1.1284 TD
[(12.)-500.5(Keeley)-289(V,)-282.4(Crooks)-281.6(S,)-277.6(Locke)-285.5(J,)-279.9(Veigas)-283.9(D,)-282.4(Riches)-281(K,)-282.4(Hilliam)]TJ
1.7505 -1.1223 TD
[(R.)-669.8(A)-666.5(quality)-668.3(of)-667.4(life)-664.7(measure)-673.4(for)-663.8(limb)-669.9(lymphoedema)]TJ
0 -1.1284 TD
[(\(LYMQOL\).)-343(J)-328.6(Lymphoedema)-338.5(2010;)-335.6(5:2637.)]TJ
-1.7505 -1.1223 TD
[(13.)-500.5(Rabin)-478.8(R,)-474.6(Charro)-478(F.)-478.8(EQ-5D:)-477.3(A)-471.4(measure)-484.3(of)-472.2(health)-477.8(status)]TJ
1.7505 -1.1284 TD
[(from)-334.1(the)-339.5(EUROQoL)-331.5(Group.)-340.2(Ann)-331.4(Med)-333.3(2001;)-335.6(33:337343.)]TJ
-1.7505 -1.1223 TD
[(14.)-500.5(Thomas)-402.1(C,)-401.4(Narahari)-403.7(S,)-399.6(Bose)-405.1(K,)-398.2(Vivekananda)-403.7(K,)-404.3(Nwe)-398.1(S,)]TJ
1.7505 -1.1284 TD
[(West)-269.9(D,)-264.1(Kwasny)-263.5(M,)-261.7(Kundu)-264.6(R.)-267.3(Comparison)-267(of)-264.9(three)-261(quality)]TJ
0 -1.1223 TD
[(of)-472.2(life)-469.5(instruments)-473.8(in)-469.4(lymphatic)-471.1(lariasis:)-474.6(DLQI,)-471.6(WHO-)]TJ
0 -1.1284 TD
[(DAS)-268.7(2.0,)-262.7(and)-260.8(LFSQQ.)-267.8(PLoS)-264.4(Negl)-268.1(Trop)-260.9(Dis)-262.8(2014;)-268.5(8:e2716.)]TJ
-1.7505 -1.1223 TD
[(15.)-500.5(Pannier)-538.6(F,)-539.8(Hoffman)-535.5(B,)-535.6(Stang)-537.9(A,)-532.4(Jockel)-538.5(K-H,)-536.6(Rabe)-538.3(E.)]TJ
1.7505 -1.1284 TD
[(Prevalence)-417.5(of)-411.3(Stemmer)-415.8(Sign)-411.5(in)-414.5(general)-411.8(population.)-412.7(Phle-)]TJ
0 -1.1223 TD
[(bologie)-339.5(2007;)-329.5(36:289292.)]TJ
-1.7505 -1.1284 TD
[(16.)-500.5(S)-15.2(a)-10.4(n)-6.2(d)-12.3(e)-10.4(r)-8.6(s)-11.5(o)-12.3(n)-329.5(J)-11.5(,)-329.4(T)-8.1(u)-12.3(t)-11.8(tl)-17.4(e)-333.7(N)-7.8(,)-335.5(B)0(o)-17.3(x)-329.5(R)-11(,)-329.4(R)-11(e)-10.4(u)-12.3(l)-11.8(-)-8.6(H)-13.9(ir)-20.3(c)-10.4(h)-6.2(e)-333.7(H)-7.8(M)-11.6(,)-329.4(L)-14.2(a)-10.4(a)-10.4(k)-12.3(so)-17.7(n)]TJ
1.7505 -1.1223 TD
.0119 Tc
[(E-L.)-384.6(Th)5.7(e)-382.8(p)-.4(it)11.9(t)-5.5(i).1(ng)-378.6(Test)11.9(:)-389.8(A)-2(n)-378.6(i).1(nv)5.7(estig)5.7(atio)5.7(n)-384.7(o)-.4(f)-380.9(a)-382.8(uns)11.9(tand)5.7(ard)5.7(-)]TJ
0 -1.1284 TD
.0104 Tc
[(ized)-319.1(as)10.4(s)-6.4(e)0(ssment)-318.5(of)-315.3(lym)10.4(p)-7.8(hoedema.)-312.9(Lymphol)10.4(o)-7.6(g)-1.9(y)-313(2)4.2(015;)-318.5(4)4.2(8:)]TJ
0 -1.1223 TD
.0123 Tc
[(175)6.1(1)6.1(83.)]TJ
-1.7505 -1.1284 TD
0 Tc
[(17.)-500.5(International)-468.2(Society)-468.6(of)-460.1(Lymphology.)-466(The)-464(diagnosis)-466.1(and)]TJ
1.7505 -1.1223 TD
[(treatment)-709.4(of)-710.1(peripheral)-706.8(lymphedema:)-707.5(2013)-708.1(Consensus)]TJ
0 -1.1284 TD
[(Document)-559.1(of)-557.6(the)-553(International)-559.7(Society)-560.1(of)-551.5(Lymphology.)]TJ
0 -1.1223 TD
[(Lymphology)-337.8(2013;)-329.5(46:)-335.3(111.)]TJ
-1.7505 -1.1284 TD
[(18.)-500.5(International)-468.2(Society)-468.6(of)-460.1(Lymphology.)-466(The)-464(diagnosis)-466.1(and)]TJ
1.7505 -1.1223 TD
[(treatment)-556.9(of)-545.4(peripheral)-554.3(lymphoedema:)-555.2(Consensus)-550.5(docu-)]TJ
0 -1.1284 TD
[(ment)-467.3(of)-460(the)-461.5(International)-468.2(Society)-462.5(of)-466.1(Lymphology:)-465.5(Lym-)]TJ
0 -1.1223 TD
[(phology)-335.9(2016;)-335.6(49:170184.)]TJ
-1.7505 -1.1284 TD
[(19.)-500.5(Fukazawa)-357.9(R,)-358.8(Koyama)-352(S,)-356.9(Kanetaka)-354.5(H,)-355.5(Umahara)-358.7(T,)-355.9(Hanyu)]TJ
1.7505 -1.1223 TD
[(H,)-495.8(Iwamoto)-502.2(T.)-490(Leg)-500.6(oedema)-494.9(detected)-498.7(on)-494.3(comprehensive)]TJ
0 -1.1284 TD
[(geriatric)-382.8(assessment)-381.6(for)-377.1(elderly)-376.6(outpatients)-378.9(and)-376.7(its)-376.6(associ-)]TJ
0 -1.1223 TD
[(ated)-337.8(risk)-336.9(factors.)-335.9(Jpn)-328.9(J)-334.7(Geriatr)-337.8(2013;)-335.6(50:384339.)]TJ
9.843 0 0 9.843 441.014 251.3196 Tm
[(Address)-337.6(correspondence)-337.8(to:)]TJ
/F11 1 Tf
1.7913 -1.1174 TD
[(Christine)-340.4(Moffatt,)-335.3(CBE)]TJ
-.9792 -1.1116 TD
[(School)-336.2(of)-336.4(Social)-330.6(Scien)-8(ces)]TJ
-1.2614 -1.1116 TD
[(Nottingham)-341.6(Trent)-334.7(University)]TJ
2.6725 -1.1174 TD
[(50)-330.5(Shakespeare)-338.9(Street)]TJ
-.0461 -1.1116 TD
[(NG1)-339.3(4FQ)-333.7(Nottingham)]TJ
2.3903 -1.1116 TD
[(United)-331.4(Kingdom)]TJ
-7.9311 -2.1253 TD
(E-mail:)Tj
/F4 1 Tf
3.3982 0 TD
(christine.moffatt@ntu.ac.uk)Tj
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(134)Tj
46.3153 0 TD
[(MOFFATT)-333.6(ET)-338.7(AL.)]TJ
ET
endstream
endobj
78 0 obj
<>stream
8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0
b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup`
E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn
6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O(
l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~>
endstream
endobj
81 0 obj
<>stream
htWyxSeO{:½Ev&@t7I&i4{MmJ}ta)PV
:Μtw~3͓9w~^X^^^o3p嶄#{qn=7z
%S3A6ڳi^^M;s_~k7y-!;.X L͊dc edyl|_H/U'&$fRDmbdRyqԄX~j``y1?gkb=a4k#m.0bmeYXa,#uuyXi^ONsMzJԅ'.ء1'so3OyKf=kƬ=.Ξ3[ʝ˕qoY>6gbnܫsg=Xy/ϳ$+W{x~淧*c5Thi*t$ITD1/Cy0-z-nXּ^B>ZWr v@i\GYqKE!C8\?+H(xy(`s>.5:;s[23Ğ&&WfI;SﻻnV|fXvG#"H=p(74/"_D3C./ 6|(p{xXipV[],r;1RJDg*#Befo7+2FԔ(*^wPu/,%Q#p0yq9-z)jPa5>":?M{4JBBL&]1-hk>ŅPPpqލSv`.C}sA"1"^َZA/FY9w!
.n3uqt6ges3
_y9o*o;yVhxJSRtY-q[uM+u03\9$3J\uB){ɝ\țRKqBוa*-ǖsgHiؠ1 N-\P()
2Oe3pМn{1q$Bʞ8+҇*=8٩X QiVZ??Kv5B| Eb뱵zڬe\ae$,+
e_2:ЂJd=(
FaHӎҠog@VK&]!MF۳0/%0/`cwOC:L@ Ň5BE1C8M-R)oGNvHY|` YlM6;;ϧt
Vkxo".Xs~=fo